document incorporate referencepart iii portion registrant proxy statement annual meeting shareholder file day close registrant fiscal year proxy statement incorporate reference report reportitem business general segment business geographic area raw material patent trademark seasonality competition research development environment regulation available information risk factor unresolved staff comment property legal proceeding safety disclosure executive officer registrant market registrant common equity relate stockholder matter issuer purchase equity security select financial datum management discussion analysis financial condition result operation quantitative qualitative disclosure market risk financial statement supplementary data change disagreement accountant account financial disclosure control procedure information iii director executive officer corporate governance executive compensation security ownership certain beneficial owner management relate stockholder matter certain relationship relate transaction director independence principal accountant fee service exhibit financial statement schedule signature exhibit index item business general johnson johnson subsidiaries company approximately employee worldwide engage research development manufacture sale broad range product health care field johnson johnson hold company operate company conduct business virtually country world company primary focus product relate human health wellbee johnson johnson incorporate state new jersey executive committee johnson johnson principal management group responsible strategic operation allocation resource company committee oversee coordinate activity company business segment consumer pharmaceutical medical device strategic parameter provide committee senior management group international operating company responsible strategic plan daytoday operation company subsidiary business segment limited exception manage resident country locate segment business company organize business segment consumer pharmaceutical medical device additional information require item incorporate reference narrative tabular description segment operate result item management discussion analysis result operation financial condition report note segment business geographic area note consolidated financial statement include item report consumer consumer segment include broad range product baby care oral care skin care overthecounter pharmaceutical womens health wound care market baby care include johnson line product oral care include listerine product line major brand skin care include aveeno clean clear dabao johnsons adult petite marseillais lubriderm neutrogena roc product lines overthe counter medicine include broad family tylenol acetaminophen product sudafe cold flu allergy product benadryl zyrtec allergy product motrin ibuprofen product pepcid line heartburn product major brand women health outside north america stayfree carefree sanitary pad tampon brands wound care brand include bandaid brand adhesive bandage neosporin aid product line product market general public sell retail outlet distributor world pharmaceutical pharmaceutical segment focus therapeutic area immunology rheumatoid arthritis inflammatory bowel disease psoriasis infectious disease vaccine hiv hepatitis respiratory infection tuberculosis neuroscience alzheimer disease mood disorder schizophrenia oncology prostate cancer hematologic malignancy lung cancer cardiovascular metabolic disease thrombosis diabete product segment distribute directly retailer wholesaler hospital health care professional prescription use key product pharmaceutical segment include remicade infliximab treatment number immunemediate inflammatory disease simponi golimumab subcutaneous treatment adult moderate severe rheumatoid arthritis active psoriatic arthritis active ankylose spondylitis moderately active severely active ulcerative colitis simponi aria golimumab intravenous treatment adult moderate severe rheumatoid arthritis stelara ustekinumab treatment adult moderate severe plaque psoriasis active psoriatic arthritis adolescent moderate severe psoriasis olysiosovriadsimeprevir combination treatment chronic hepatitis adult patient prezista darunavir edurant rilpivirine prezcobixrezolsta darunavircobicistat antiretroviral medicine treatment human immunodeficiency virus hiv combination antiretroviral product sirturo bedaquiline diarylquinoline antimycobacterial drug indicate combination therapy adult year pulmonary multidrug resistant tuberculosis mdrtb concerta methylphenidate hcl extend release tablet cii treatment attention deficit hyperactivity disorder invega paliperidone extendedrelease tablet treatment schizophrenia schizoaffective disorder invega sustennaxeplion paliperidone palmitate treatment schizophrenia schizoaffective disorder adult invega trinza paliperidone palmitate treatment schizophrenia patient adequately treat invega sustenna month risperdal consta risperidone longacte injection treatment ofschizophrenia maintenance treatment bipolar disorder adult velcade bortezomib treatment multiple myeloma use combination rituximab cyclophosphamide doxorubicin prednisone treatment adult patient previously untreate mantle cell lymphoma zytiga abiraterone acetate combination prednisone treatment metastatic castrationresistant prostate cancer imbruvica ibrutinib oral oncedaily therapy approve use treat certain bcell malignancy blood cancer waldenstrm macroglobulinemia darzalextm daratumumab treatment double refractory multiple myeloma yondelis trabectedin treatment patient unresectable metastatic liposarcoma leiomyosarcoma receive prior anthracycline contain regimen procrit epoetin alfa sell outside eprex stimulate red blood cell production xarelto rivaroxaban oral anticoagulant prevention deep vein thrombosis dvt lead pulmonary embolism patient undergo hip knee replacement surgery reduce risk stroke systemic embolism patient nonvalvular atrial fibrillation treatment reduction risk recurrence dvt invokana canagliflozin treatment adult type diabete invokametvokanamet canagliflozinmetformin hcl combination therapy fix dose canagliflozin metformin hydrochloride treatment adult type diabete medicine develop collaboration strategic partner license company maintain active lifecycle development program medical device medical device segment include broad range product orthopaedic surgery cardiovascular diabetes care vision care field product distribute wholesaler hospital retailer principally professional field physician nurse hospital eye care professional clinic include orthopaedic product general surgery biosurgical endomechanical energy product electrophysiology product treat cardiovascular disease sterilization disinfection product reduce surgical infection diabete care product blood glucose monitor insulin delivery product disposable contact lense geographic areas business johnson johnson conduct operate company locate country include virtually country world product sell international business include describe segment business consumer pharmaceutical medical device principal market product method distribution international business vary country culture product sell international business include develop united states subsidiary abroad investment activity country outside subject high risk comparable activity investment commercial climate influence financial instability international economy restrictive economic policy political legal system uncertaintie raw material raw material essential company business generally readily available multiple source exception temporary unavailability raw material likely material adverse effect financial result company patent company subsidiary practice obtain patent protection product process possible licensed number patent relate product manufacturing process aggregate believe material importance company operation business sale company large product remicade infliximab account approximately company total revenue fiscal accordingly patent relate product believe material company set patent relate specifically remicade infliximab set patent coowne janssen biotech inc whollyowne subsidiary johnson johnson nyu langone medical center nyu janssen biotech inc exclusive license nyu interest patent patent expire country outside united statesin united states late patent expire september patent stand reject subject reexamination proceeding institute party united states patent trademark office proceeding go second set patent specifically relate remicade grant kennedy institute rheumatology europe canada australia united states janssen biotech inc license exclusive human antitnf antibodiesand semiexclusive nonhuman antitnf antibodie patent expire outside united states united states validity patent challenge certain claim invalidate review patent office world subject litigation canada company expect additional extension available describe patent specifically relate remicade remicade relate patent discuss find invalid patent relied prevent introduction biosimilar version remicade extensive description legal matter patent relate remicade note legal proceeding intellectual property pharmaceutical remicaderelate case note consolidated financial statement include item report addition compete immunology market remicade company currently market stelara ustekinumab simponi golimumab simponi aria golimumab generation immunology product remain patent live year trademark company subsidiary practice sell product trademark obtain protection trademark available mean trademark protect registration united states country product market company consider trademark aggregate material importance operation business seasonality worldwide sale reflect significant degree seasonality spend heavy fourth quarter year quarter reflect increase spending decision principally advertise research development activity competition product line company subsidiary compete company locally globally competition exist product line regard number size compete company involve competition research internally externally source involve development improvement new exist product process particularly significant development new innovative product protect underlie intellectual property company product portfolio important company success area business competitive environment require substantial investment continue research addition development maintenance customer demand company consumer product involve significant expenditure advertising promotion research development research activity represent significant company business research development expenditure relate process discover testing develop new product improve exist product demonstrate product efficacy regulatory compliance prior launch company remain committed invest research development aim deliver high quality innovative product worldwide cost research development activity amount billion billion billion fiscal year respectively research facility locate united states belgium brazil canada china france germany india israel japan netherlands singapore switzerland united kingdom environment company subject variety international environmental protection measure company believe operation comply material respect applicable environmental law regulation companys compliance requirement change past year expect material effect capital expenditure cash flow earning competitive position regulation company business subject vary degree governmental regulation country operation conduct general trend increasingly stringent regulation drug device cosmetic industry long subject regulation federal state agency primarily product safety efficacy manufacturing advertising labeling safety report exercise broad regulatory power food drug administration fda continue result increase amount test documentation require forfda approval new drug device correspond increase expense product introduction similar trend evident major market outside cost human health care continue subject study investigation regulation governmental agency legislative body world attention focus drug price profit program encourage doctor write prescription particular drug recommend use purchase particular medical device payer potent force market place increase attention pay drug medical device price appropriate drug medical device utilization quality cost health care generally government agency continue implement extensive requirement patient protection affordable care act aca positive negative impact healthcare industry remain uncertain provision aca ultimately affect industry regulatory agency purview company operate administrative power subject action product withdrawal recall seizure product civil criminal sanction case company subsidiary deem advisable initiate product recall addition business practice health care industry come increase scrutiny particularly united states government agency state attorney general result investigation prosecution carry risk significant civil criminal penalty company rely global supply chain production distribution process complex subject increase regulatory requirement affect source supply pricing material company product process subject lengthy regulatory approval available information company main corporate website address wwwjnjcom copy company quarterly report form annual report current report form file furnish securities exchange commission sec amendment foregoing provide charge shareholder submit write request secretary principal executive office company call company sec filing available company website wwwinvestorjnjcomgovsecfilingscfm soon reasonably practicable electronically file furnish sec sec filing available secs website wwwsecgov addition write charter audit committee compensation benefit committee nominate corporate governance committee regulatory compliance government affair committee science technology sustainability committee board director company principle corporate governance code business conduct employee code business conduct ethic member board director executive officer corporate governance material available wwwinvestorjnjcomgov materialscfm company website provide charge shareholder submit write request provide information company website deem report incorporate filing company make sec item risk factor company face number uncertainty risk difficult predict outside company control addition information report company filing sec investor consider carefully factor set forth exhibit report investor realize known unknown risk uncertainty materialize company business result operation financial condition adversely affect item unresolved staff comment applicable item property company subsidiary operate manufacturing facility occupy approximately million square foot floor space manufacturing facility industry segment company business approximately follow square foot segment thousand consumer pharmaceutical medical device worldwide total united states facility consumer segment pharmaceutical segment medical device segment outside united states facility consumer segment pharmaceutical segment medical device segment location manufacture facility major geographic area world follow number square feet geographic area facility thousands united states europe western hemisphere exclude africa asia pacific worldwide total addition manufacture facility discuss company maintain numerous office warehouse facility world research facility discuss item report business research development company subsidiary generally seek manufacture facility principally nonus location lease office warehouse facility lease company engage contract manufacturer company commit maintain property good operating condition repair facility utilize mcneilppc inc johnson johnson consumer inc mcneilppc continue operate consent decree sign fda govern certain mcneil consumer healthcare manufacturing operation require mcneilppc remediate facility operate lancaster pennsylvania fort washington pennsylvania las piedras puerto rico consent decree fort washington facility voluntarily shut april subsequently product transfer manufacture site successfully reintroduce market mcneilppc successfully complete requirement contain consent decree workplan lancaster las piedras manufacturing site complete step require thirdparty certification fort washington plant thirdparty cgmp expert submit write certification fda manufacturing site follow fda inspection mcneilppc receive notification fda manufacture facility conformity applicable law regulation commercial production fort washington start september consent decree receive notice fda compliance applicable law regulation facility subject fiveyear audit period thirdparty cgmp expert thirdparty expert continue reassess site time year discussion legal proceeding relate matter find note legal proceeding government proceeding mcneil consumer healthcare note consolidated financial statement include item report information lease obligation note rental expense lease commitment note consolidated financial statement include item report segment information addition property plant andequipment contain note segment business geographic area note consolidated financial statement include item report item legal proceeding information call item incorporate reference information set forth note legal proceeding note consolidated financial statement include item report addition johnson johnson subsidiaries time time party government investigation inspection proceeding relate environmental matter include compliance applicable environmental law item safety disclosure applicable executive officer registrant list executive officer company february family relationship executive officer arrangement understand executive officer person pursuant executive officer select annual meeting board director executive officer elect board hold office year respective successor elect qualified early resignation removal information regard director company include information alex gorsky incorporate reference material caption item election director proxy statement age position dominic caruso member executive committee vice president finance chief financial officera peter fasolo member executive committee vice president global human resourcesb alex gorsky chairman board directors chairman executive committee chief executive officer sandra peterson member executive committee group worldwide chairmanc paulus stoffels member executive committee chief scientific officer worldwide chairman pharmaceuticalsd michael ullmann member executive committee vice president general counsele caruso join company company acquire centocor inc time acquisition senior vice president finance centocor caruso name vice president finance orthomcneil pharmaceutical inc subsidiary company vice president group finance company medical device diagnostic group caruso name vice president company group finance organization caruso member executive committee vice president finance chief financial officer fasolo join company vice president worldwide human resource cordis corporation subsidiary company name vice president global talent management company leave johnson johnson join kohlberg kravis roberts chief talent officer fasolo return company vice president global human resource member executive committee peterson join company group worldwide chairman member executive committee responsibility consumer group company consumer medical device business vision care diabete care franchise functions johnson johnson supply chain information technology wellness prevention global strategic design prior join johnson johnson peterson extensive global career healthcare consumer good consulting recently chairman chief executive officer bayer cropscience germany previously serve president chief executive officer bayer medical care president bayer healthcare diabetes care division join bayer peterson hold number leadership role medco health solution previously know merckmedco responsibility application information technology healthcare system stoffels join company acquisition virco tibotec chief executive officer virco chairman tibotec appoint company group chairman global virology lead development prezista intelence lead product treatment hiv assume role company group chairman pharmaceutical responsibility worldwide research development central nervous system internal medicine franchise stoffels appoint global head research development pharmaceutical worldwide chairman pharmaceutical responsibility company therapeutic pipeline global research development strategic business development stoffel appoint chief scientific officer responsibility enterprisewide innovation product safety member executive committee ullmann join company corporate attorney law department appoint corporate secretary serve role time hold management position law department name general counsel medical device diagnostic ullmann appoint vice president general counsel member executive committee item market registrant common equity relate stockholder matter issuer purchase equity security february record holder common stock company additional information call item incorporate reference follow section report item management discussion analysis result operation financial condition liquidity capital resource dividend information common stock market price note common stock stock option plan stock compensation agreement note consolidated financial statement include item item security ownership certain beneficial owner management relate stockholder matter equity compensation plan information issuer purchase equity securities october company announce board director approve share repurchase program authorize company purchase billion company common stock share repurchase place open market time time base market condition repurchase program time limit suspend period discontinue time follow table provide information respect common stock purchase company fiscal fourth quarter common stock purchase open market systematic plan meet need company compensation program repurchase include stockforstock option exercise settle fiscal fourth quarter total number maximum number share unit approximate dollar purchase value share total number publicly unit share avg price announce plan purchase period purchase pay share program plan program september october october november november january total fiscal fourth quarter company repurchase aggregate share johnson johnson common stock openmarket transaction share purchase pursuant repurchase program publicly announce october share purchase openmarket transaction systematic plan meet need company compensation program january aggregate share purchase total billion inception repurchase program announce october january maximum number share purchase plan base closing price johnson johnson common stock new york stock exchange december shareitem select financial datum summary operation statistical data dollar million share amount sale customer sale customer international total sale cost product sell sell marketing administrative expense research development expense inprocess research development interest income interest expense net portion capitalize income expense net restructure earning provision taxis income provision taxis income net earning add net loss attributable noncontrolle interest net earning attributable johnson johnson percent sale customer dilute net earning share common stock percent return average shareholder equity percent increase decrease previous year sale customer dilute net earning share supplementary balance sheet datum property plant equipment net addition property plant equipment total asset longterm debt operate cash flow common stock information dividend pay share shareholder equity share market price share yearend close average share outstanding million basic diluted employee thousand attributable johnson johnson amount reclassify conform current year presentation item management discussion analysis result operation financial condition organization business segment description company business segment johnson johnson subsidiaries company approximately employee worldwide engage research development manufacture sale broad range product health care field company conduct business virtually country world primary focus product relate human health wellbee company organize business segment consumer pharmaceutical medical device consumer segment include broad range product baby care oral care skin care overthecounter pharmaceutical womens health wound care market product market general public sell retail outlet distributor world pharmaceutical segment focus therapeutic area include immunology infectious disease neuroscience oncology cardiovascular metabolic disease product segment distribute directly retailer wholesaler hospital health care professional prescription use medical device segment include broad range product orthopaedic surgery cardiovascular diabetes care vision care field distribute wholesaler hospital retailer principally professional field physician nurse hospital eye care professional clinic executive committee johnson johnson principal management group responsible strategic operation allocation resource company committee oversee coordinate activitie consumer pharmaceutical medical device business segment product line company compete company locally globally world competition exist product line regard number size compete company involve competition research involve development improvement new exist product process particularly significant development new innovative product protect underlie intellectual property company product portfolio important company success area business competitive environment require substantial investment continue research addition development maintenance customer demand company consumer product involve significant expenditure advertising promotion management objective company manage strategic framework credo foundation company believe strategic operating principle broadly base human health care manage business long term decentralize management approach commit people value crucial successfully meeting demand rapidly evolve market compete end management focus longterm strategic growth driver create value innovation expand global reach local focus excellence execution lead purpose company broadly base human health care commit create value develop accessible high quality innovative product service new product introduce past year account approximately sale billion sale invest research development reflect management commitment deliver new differentiate product service meet evolve health care need sustain company longterm growth diverse business operate company locate country key driver company success maintain company decentralize management approach time leverage extensive resource enterprise position company innovate execute strategic plan reach market globally address need challenge local market order remain leader health care company strive maintain purposedriven organization commit develop global business leader achieve growth objective business manage longterm order sustain market leadership position enable growth provide endure source value shareholder credo unify johnson johnson employee achieve objective provide common set value serve foundation company responsibility patient consumer health care professional employee community shareholder company believe foundational value strategic framework longterm growth driver overall mission improve quality life people world enable johnson johnson continue leader health care industryresult operation analysis consolidate sale worldwide sale decrease billion compare increase sale change consist follow sale increasedecrease volume price currency total introduction competitive product company hepatitis product olysiosovriad simeprevir incivo telaprevir negative impact worldwide operational sale growth impact acquisition divestiture worldwide operational sale growth negative sale company hepatitis product olysiosovriad simeprevir incivo telaprevir positive impact divestiture orthoclinical diagnostic business negative impact worldwide operational growth acquisition synthes inc net relate divestiture increase worldwide operational growth sale company billion billion billion represent increase sale international company billion billion billion represent decrease increase fiveyear compound annual growth rate worldwide international sale respectively tenyear compound annual growth rate worldwide international sale respectively sale company europe experience decline compare prior year include operational growth offset negative currency impact sale company western hemisphere exclude experienced decline compare prior year include operational growth offset negative currency impact sale company asiapacific africa region experience decline compare prior year include operational growth negative currency impact result benefit inclusion week note consolidated financial statement annual closing date detail company estimate fiscal year growth rate enhance approximately additional week add day sale add week worth operating cost net earning impact negligible company wholesaler distribute product segment represent approximately respectively total consolidated revenue company customer represent total consolidated revenue health care reform july internal revenue service issue final regulation brand prescription drug fee annual nontax deductible fee impose entity engage business manufacturing import brand prescription drug cover entity enact section patient protection affordable care act final regulation accelerate expense recognition criterion fee obligation year year fee pay year sale calculate fee occur change impact cover entity result need entity record additional expense fee expense pay company accrue additional million fiscal quarter change fee associate accelerated expense pay schedule cash impact analysis sale business segment consumer segment consumer segment sale billion decrease include operational growth offset negative currency impact consumer segment sale billion increase international sale billion decrease include operational growth offset negative currency impact divestiture negative impact worldwide consumer segment operational growth major consumer franchise sale change dollar million otc skin care baby care oral care womens health wound careother total consumer sale overthecounter otc franchise sale billion decrease compare prior year include operational growth negative currency impact operational growth primarily drive analgesic upper respiratory include zyrtecand digestive health product mcneilppc inc johnson johnson consumer inc mcneilppc continue operate consent decree sign food drug administration fda govern certain mcneil consumer healthcare manufacturing operation require mcneilppc remediate facility operate lancaster pennsylvania fort washington pennsylvania las piedras puerto rico consent decree february thirdparty expert submit write certification fda manufacture site follow fda inspection mcneilppc receive notification fda manufacture facility conformity applicable law regulation consent decree receive notice fda compliance applicable law regulation facility subject fiveyear audit period thirdparty cgmp expert thirdparty expert continue reassess site time year skin care franchise sale billion decrease compare prior year include operational growth negative currency impact operational growth primarily sale growth neutrogena aveeno product partially offset low sale china baby care franchise sale billion decrease compare prior year include operational growth negative currency impact operational growth primarily new product launch partially offset competition china oral care franchise sale billion decrease compare prior year include operational growth negative currency impact operational growth drive increase sale listerine productsattributable geographical expansion new product successful marketing campaign women health franchise sale billion decrease compare prior year include operational growth negative currency impact operational growth outside drive new product launch successful marketing campaign wound careother franchise sale billion decrease primarily splenda andbenecol divestiture consumer segment sale billion decrease include operational growth offset negative currency impact consumer segment sale billion decrease international sale billion decrease include operational growth offset negative currency impact pharmaceutical segment pharmaceutical segment sale billion decrease include operational growth offset negative currency impact sale billion increase international sale billion decrease include operational growth offset negative currency impact pharmaceutical segment operational growth negatively impact introduction competitive product company hepatitis product olysiosovriad simeprevir incivo telaprevir positively impact adjustment previous reserve estimate include manage medicaid rebate primarily cardiovascularmetabolismother therapeutic area divestiture negative impact worldwide pharmaceutical segment operational growth major pharmaceutical therapeutic area sale change dollar million total immunology remicade simponisimponi aria stelara immunology total infectious disease edurant olysiosovriad prezista prezcobixrezolsta infectious disease total neuroscience concertamethylphenidate invegapaliperidone invega sustennaxeplioninvega trinza risperdal consta neuroscience total oncology imbruvica velcade zytiga oncology cardiovascular metabolism xarelto invokana invokamet procriteprex total pharmaceutical sale prior year amount reclassify conform current year presentation percentage great previously refer immunology product achieve sale billion represent increase compare prior yearimmunology product growth include operational growth negative currency impact increase sale stelara ustekinumab simponisimponiaria golimumab market growth increase penetration simponi aria growth partially offset low remicade infliximab salesto company distributor primarily weakening euro biosimilar competition europe patent remicade certain country europe expire february biosimilar version remicade introduce certain market outside united states result reduction sale remicade market additional biosimilar competition likely result reduction remicade sale market outside united states time possible introduction biosimilar version remicade united states subject enforcement patent right approval fda compliance day notice provision biologic price competition innovation act bpcia february arthritis advisory committee fda recommend vote approve investigational biosimilar infliximab eligible indication united states risk competitor launch biosimilar version remicade follow fda approval subject compliance day notice provision bpcia valid patent place introduction market biosimilar version remicade result reduction sale remicade sale remicade billion launch biosimilar version remicade expect material adverse effect company result operation cash flow note consolidated financial statement legal matter remicade patent infectious disease product sale billion decline include operational decrease negative currency impact competitive product company hepatitis product olysiosovriad simeprevir incivo telaprevir significant negative impact sale continue negative impact future sale decline hepatitis sale partially offset sale growth edurantrilpivirine sale prezista prezcobixrezolsta darunavircobicistat neuroscience product sale billion decrease include operational growth negative currency impact sale growth concertamethylphenidate primarily therapeutic equivalence reclassification generic competitor fda november strong sale invega sustennaxeplioninvega trinza paliperidone palmitate primarily increase market share launch invega trinza neuroscience product sale negatively impact divestiture nucynta tapentadol low sale risperdal consta risperidone oncology product achieve sale billion represent increase compare prior year oncology product growth include operational growth negative currency impact contributor growth strong sale imbruvica ibrutinib approval new indication additional country launch strong patient uptake additionally sale zytiga abiraterone acetate grow market growth partially offset share decline strong growth asia latin america partially offset low sale europe competition cardiovascularmetabolismother product achieve sale billion represent increase compare prior year strong sale xareltorivaroxaban invokanainvokamet canagliflozin procriteprex epoetin alfa sale impact competition company advanced pipeline regulatory submission approval new drug additional indication exist drug follow product chemical indication approv approv filing filing treatment double refractory multiple darzalex daratumumab myeloma use combination antiretroviral agent treatmentnave adolescent patient edurant rilpiravine aged year hiv infection imbruvica ibrutinib treatment waldenstrm macroglobulinemia treatment patient relapse refractory chronic lymphocytic leukemia cll small lymphocytic lymphoma combination bendamustine rituximab use treatmentnave patient chronic lymphocytic leukemia invega trinza paliperidone atypical antipsychotic injection administer palmitate time year treatment schizophrenia oncedaily therapy combine fix dose canagliflozin metformin hydrochloride extend release treatment adult type invokamet canagliflozin diabetes use combination antiretroviral medicinal product treatment human prezcobix darunavircobicistatimmunodeficiency virus hiv simponi golimumab treatment nonradiographic axial spondyloarthritis treatment adolescent moderate stelara ustekinumab tosevere psoriasis treatment adult patient moderately severely active crohn disease use combination rituximab cyclophosphamide doxorubicin prednisone treatment adult patient previously velcade bortezomib untreated mantle cell lymphoma treatment patient unresectable yondelis trabectedin metastatic liposarcoma leiomyosarcoma pharmaceutical segment achieve sale billion represent increase prior year strong operational growth negative currency impact sale billion increase international sale billion increase include operational growth negative currency impact pharmaceutical segment sale include positive adjustment previous estimate manage medicaid rebate negatively impact pharmaceutical operational sale growth compare prior year sale company hepatitis product olysiosovriad simeprevir incivo telaprevir positive impact operational growth pharmaceutical segment medical device segment medical device segment sale billion decrease include operational decline negative currency impact sale billion decrease compare prior year international sale billion decrease compare prior year operational decrease negative currency impact divestiture orthoclinical diagnostic cordis business negative impact respectively worldwide operational growth medical device segment compare major medical device franchise sale change dollar million orthopaedic hip knee trauma spine surgery advanced general specialty vision care cardiovascular diabetes care diagnostic total medical device sale prior year amount reclassify conform current year presentation orthopaedic franchise sale billion decrease include operational growth negative currency impact operational growth europe region primarily drive sale hip primary stem platform attune knee system trauma tfna nailing system sport medicine orthoviscmonovisc product growth negatively impact soft demand reduction customer inventory level primarily china continue pricing pressure surgery franchise sale billion decrease include operational growth negative currency impact operational growth advanced surgery drive endocutter biosurgical energy product primarily attributable market growth increase penetration certain market new product launch operational growth specialty surgery primarily drive mentor product growth partially offset low sale woman health urology product general surgery vision care franchise sale billion decrease include operational growth negative currency impact operational growth major region primarily drive new product launch partially offset low price cardiovascular franchise sale billion decrease represent operational decline negative currency impact strong operational growth electrophysiology business drive market growth success thermocool smarttouchcatheter offset impact divest cordis business company complete divestiture cordis business cardinal health october cordis business generate annual net revenue approximately million million respectively additional detail note consolidated financial statement diabetes care franchise sale billion decrease represent operational decline negative currency impact operational decline primarily low price partiallyoffset success animas vibe product june company divest orthoclinical diagnostic business diagnostic franchise carlyle group additional detail note consolidated financial statement medical device segment sale billion decrease include operational decline negative currency impact sale billion decrease compare prior year international sale billion decline compare prior year operational growth offset negative currency impact divestiture orthoclinical diagnostic business negative impact operational growth medical device segment analysis consolidate earning provision taxis income consolidated earning provision taxis income decrease billion compare billion decrease decrease primarily attributable significantly low sale olysiosovriad simeprevir negative currency impact restructure charge billion high intangible asset writedown billion compare decrease partially offset low net litigation expense billion low synthe integration cost billion positive adjustment billion previous reserve estimate include manage medicaid rebate high gain billion divestiture compare prior year fiscal year include high gain billion primarily divestiture cordis business splenda brand divestiture nucynta versus gain record divestiture orthoclinical diagnostic business brand additionally include additional year brand prescription drug fee billion consolidated earning provision taxis income increase billion compare billion increase earning provision taxis income favorable strong sale volume growth particularly sale olysiosovriad simeprevir positive mix high sale high margin product pharmaceutical business divestiture low margin business cost reduction effort business additionally include high net gain divestiture billion primarily divestiture orthoclinical diagnostic business low litigation expense billion low inprocess research development cost billion low expense billion relate depuy asr hip program compare fiscal year partially offset inclusion additional year brand prescription drug fee billion billion high synthe integrationtransaction cost fiscal year include net gain billion equity investment transaction primarily sale elan american depositary share percent sale consolidated earning provision taxis income versus cost product sell sell marketing administrative expense cost product sell sell marketing administrative expense percent sale follow sale cost product sell percent point increasedecrease prior year sell marketing administrative expense percent point increasedecrease prior year cost product sell percent sale increase slightly compare prior year favorable mix segment offset million associate restructuring activity medical device segment negative transactional currency low sale olysiosovriad simeprevir intangible asset amortization expense include cost product sell billion billion respectively increase percent sale sell marketing administrative expense compare prior year primarily incremental investment spending segment impact low sale olysiosovriad simeprevir partially offset favorable mix inclusion additional year brand prescription drug fee billion cost product sell percent sale decrease compare prior year primarily result positive mix high sale high margin product pharmaceutical business divestiture low margin business cost improvement business partially offset pricing impact negative transactional currency addition include inventory stepup charge billion relate synthe acquisition intangible asset amortization expense include cost product sell billion decrease percent sale sell marketing administrative expense compare prior year primarily leverage cost result growth pharmaceutical business particularly sale olysiosovriad simeprevir cost containment initiative business partially offset inclusion additional year brand prescription drug fee million fiscal quarter research development expense research development expense segment business follow dollar million sale sale sale consumer pharmaceutical medical device total research development expense percent increasedecrease prior year percent segment sale research development activity represent significant company business expenditure relate process discover testing develop new product upfront payment milestone improve exist product ensure product efficacy regulatory compliance prior launch company remain committed invest research development aim deliver high quality innovative product worldwide cost research development activity increase compare increase percent sale attributable increase investment spend primarily pharmaceutical segment low overall sale business mix worldwide cost research development activity increase compare reduction percent sale primarily strong sale growth pharmaceutical business research spend pharmaceutical segment increase absolute dollar billion compare billion primarily high level spend advance company pharmaceutical pipeline inprocess research development iprd company record iprd charge billion primarily discontinuation certain development project relate covagen company record iprd charge billion impairment iprd project relate respivert crucell mentor synthe delay discontinuation certain development project company record iprd charge billion primarily impairment iprd project relate crucell corimmun acclarent delay discontinuation certain development project income expense net income expense net account company record gain loss relate sale writedown certain investment equity security hold johnson johnson innovation jjdc inc johnson johnson development corporation gain loss divestiture transactional currency gain loss acquisitionrelate cost litigation accrual settlement royalty income change income expense net fiscal year favorable change billion compare prior year primarily low litigation expense billion low synthe integration cost billion high jjdc portfolio gain billion compare prior year additionally fiscal year include high gain billion primarily divestiture cordis business splenda brand divestiture nucynta versus gain record divestiture orthoclinical diagnostic business brand partially offset high intangible asset writedown billion change income expense net fiscal year favorable change billion compare prior year fiscal year include high net gain divestiture billion primarily divestiture ortho clinical diagnostic business low litigation expense billion low cost billion relate depuy asr hip program compare partially offset high synthe integrationtransaction cost billion high intangible asset writedown billion primarily related incivo telaprevir additionally fiscal year include high net gain billion compare equity investment transaction primarily sale elan american depositary share interest income expense interest income increase million compare high average balance cash cash equivalent marketable security high interest rate cash cash equivalent marketable security total billion end average billion compare billion average cash balance increase yearend cash balance primarily cash generate operating activity interest expense increase slightly compare average debt balance billion versus billion total debt balance end billion compare billion end high debt balance approximately billion increase commercial paper general corporate purpose primarily stock repurchase program interest income comparable prior year high balance cash cash equivalent marketable security offset low interest rate cash cash equivalent marketable security total billion end average billion compare billion average cash balance increase yearend cash balance primarily cash generate operating activity interest expense increase million compare high average debt balance average debt balance billion versus billion total debt balance end billion compare billion end high debt balance approximately billion increase borrowing november company increase borrowing capitalize favorable term capital market proceed borrowing general corporate purpose income tax segment income tax segment business follow percent segment sale dollar million consumer pharmaceutical medical device total expense allocate segment earning provision taxis income note consolidated financial statement detail amount allocate segment include interest income expense noncontrolle interest general corporate income expense consumer segment consumer segment income tax percent sale versus primarily low divestiture gain versus consumer segment tax include gain billion divestiture primarily divestiture splenda brand consumer segment include gain billion divestiture primarily divestiture brand consumer segment income tax percent sale flat prior year pharmaceutical segment pharmaceutical segment income tax percent sale versus favorable income tax primarily high gain recognize partially offset sale decline olysiosovriadsimeprevir increase investment spend negative currency impact compare include gain billion divestiture nucyntaas receipt contingent payment positive adjustment previous reserve estimate include manage medicaid rebate additionally pharmaceutical segment income tax negatively impact billion additional year brand prescription drug fee high intangible asset amortization expense billion primarily relate writedown incivo telaprevir pharmaceutical segment income tax percent sale versus favorable income tax attributable strong sale volume growth particularly sale olysiosovriad simeprevir positive sale mix high margin product cost containment initiative realize sell marketing administrative expense partially offset billion additional year brand prescription drug fee billion intangible asset writedown relate incivo telaprevir additionally include net gain billion equity investment transaction primarily sale elan american depositary share positive adjustment billion previous estimate manage medicaid rebate partially offset high writedown billion impairment iprd compare medical device segment medical device segment income tax percent sale versus primarily restructure charge billion intangible asset writedown billion related acclarent low gain billion divestiture compare medical device segment include gain billion primarily divestiture cordis business versus gain billion record divestiture orthoclinical diagnostic business income tax favorably impact low net litigation expense billion include gain litigation settlement agreement billion guidant low synthe integration cost billion compare medical device segment income tax percent sale versus favorable income tax attributable net gain billion divestiture orthoclinical diagnostic business low litigation expense billion compare restructure company announce restructuring action medical device segment expect result annualize pretax cost saving million billion majority expect realize end include approximately million saving saving provide company add flexibility resource fund investment new growth opportunity innovative solution customer patient company estimate connection plan record pretax restructuring charge approximately billion billion expect incur fiscal fourth quarter company record pretax charge billion million include cost product sell note consolidated financial statement additional detail relate restructuring provision taxis income worldwide effective income tax rate effective tax rate decrease compare primarily attributable increase taxable income low tax jurisdiction relative high tax jurisdiction tax benefit result restructure international affiliate additionally effective tax rate affect item mention increase effective tax rate compare attributable follow divestiture orthoclinical diagnostic business approximate effective tax rate litigation accrual low tax rate mix earning high tax jurisdiction primarily accrual additional year brand prescription drug fee tax deductible additional tax expense relate plan increase dividend current year foreign earning compare prior year increase effective tax rate partially offset tax benefit billion associate conor medsystem divestiture effective tax rate reduce company adjust unrecognized tax benefit result federal appeal court decision omj pharmaceutical inc litigation credit section internal revenue code note consolidated financial statement additional information settlement substantially issue relate company internal revenue service audit tax year effective tax rate reduce tax benefit associate writeoff asset tax purpose associate scios inc inclusion benefit research development tax credit control foreign corporation lookthrough provision provision enact law january retroactive january liquidity capital resource liquidity cash flow cash cash equivalent billion end compare billion end primary source use cash contribute billion decrease approximately billion cash generate operating activity offset billion net cash investing activity billion net cash financing activity billion effect exchange rate change cash cash equivalent addition company billion marketable security end billion end note consolidated financial statement additional detail cash cash equivalent marketable security cash flow operation billion result billion net earning billion noncash charge adjustment depreciation amortization stockbase compensation asset writedown primarily related acclarent venezuela writedown reduce billion net gain sale assetsbusinesse billion related defer taxis account receivable inventory additional source operate cash flow billion result decrease current noncurrent asset increase current noncurrent liability invest activity use billion primarily net purchase investment marketable security billion addition property plant equipment billion acquisition net cash acquire billion partially offset billion proceed disposal assetsbusinesse finance activity use billion primarily dividend shareholder billion billion repurchase common stock financing activity include source billion net proceed short longterm debt billion net proceed stock option exercise associate tax benefit october company announce board director approve share repurchase program authorize company purchase billion company share common stock january billion repurchase program repurchase program time limit suspend period discontinue time share acquire available general corporate purpose company intend finance share repurchase program available cash access capital market previous share repurchase program approve july authorize company purchase billion company share ofcommon stock complete april company continue access liquidity commercial paper market company shelf registration securities exchange commission enable company issue debt security warrant purchase debt security timely basis additional detail borrowing note consolidated financial statement company anticipate operate cash flow exist credit facility access capital market provide sufficient resource fund operating need concentration credit risk global concentration credit risk respect trade account receivables continue limited large number customer globally adherence internal credit policy credit limit economic challenge italy spain greece portugal southern european region impact certain payment pattern historically long experience international market total net trade account receivable balance southern european region approximately billion january billion december approximately billion january approximately billion december southern european region net trade account receivable balance relate company consumer vision care diabetes care business certain pharmaceutical medical device customer line historical collection pattern remain balance net trade account receivable southern european region negatively impact time payment certain government own support health care customer certain distributor pharmaceutical medical device local affiliate total net trade account receivable balance customer approximately billion january billion december company continue receive payment customer case late payment interest customer payment expect period time long year revenue trade receivable discount estimate period time collection allowance doubtful account increase customer immaterial date company continue work closely customer payment plan monitor economic situation appropriate action necessary financing market risk company use financial instrument manage impact foreign exchange rate change cash flow accordingly company enter forward foreign exchange contract protect value certain foreign currency asset liability hedge future foreign currency transaction primarily relate product cost gain loss contract offset gain loss underlie transaction appreciation dollar january market rate increase unrealized value company forward contract million conversely depreciation dollar january market rate decrease unrealized value company forward contract million scenario gain loss forward contract offset gain loss underlie transaction impact future anticipate earning cash flow company hedge exposure fluctuation currency exchange rate effect certain asset liability foreign currency enter currency swap contract change spread foreign interest rate companys interest rate sensitive financial instrument increase decrease unrealized value company swap contract approximately million scenario maturity gain loss swap contract offset gain loss underlie transaction impact future anticipate cash flow company enter financial instrument trade speculative purpose company policy enter contract party investment grade credit rating counterpartie contract major financial institution significant concentration exposure counterparty management believe risk loss remote company invest fix rate float rate interest earn security carry degree interest rate risk fair market value fix rate security adversely impact rise interest rate float rate security produce income predict interest rate fall basis point change spread company interest rate sensitive investment increase decrease unrealized value cash equivalent current marketable security approximately million company access substantial source fund numerous bank worldwide september company secure new day credit facility total credit available company approximate billion expire september interest charge borrowing credit line agreement base bid provide bank prime rate london interbank offer rate libor plus applicable margin commitment fee agreement material total borrowing end billion billion respectively increase borrowingsbetween result finance company share repurchase program net cash cash current marketable security net debt billion compare net cash billion total debt represent total capital shareholder equity total debt total capital shareholder equity share end compare yearend increase summary borrowing find note consolidated financial statement contractual obligation commitment company contractual obligation primarily lease debt unfunded retirement plan significant obligation satisfy obligation company use cash operation follow table summarize company contractual obligation aggregate maturity january note consolidated financial statement detail interest unfunded debt debt retirement operating dollar million obligation obligation plan lease total total tax matter note consolidated financial statement dividend company increase dividend consecutive year cash dividend pay share compare dividend share share dividend distribute follow quarter second quarter quarter fourth quarter total january board director declare regular quarterly cash dividend share payable march shareholders record february company expect continue practice pay regular cash dividend information critical accounting policy estimate management discussion analysis result operation financial condition base company consolidate financial statement prepare accordance accounting principle generally accept gaap preparation financial statement require management estimate assumption affect amount report revenue expense asset liability relate disclosure actual result differ estimate company believe understand certain key accounting policy estimate essential achieve insight company operating result financial condition key accounting policy include revenue recognition income taxis legal selfinsurance contingency valuation longlive asset assumption determine amount record pension employee benefit plan account stock base awards revenue recognition company recognize revenue product sale good ship deliver title risk loss pass customer provision certain rebate sale incentive trade promotion coupon product returnsand discount customer account reduction sale period relate sale record product discount grant base term arrangement direct indirect market participant market condition include price charge competitor rebate include medicaid rebate provision estimate base contractual term historical experience patient outcome trend analysis project market condition market serve company evaluate market condition product group product primarily analysis wholesaler thirdparty sellthrough market research datum internally generate information sale return estimate record base historical sale return information product exhibit unusual sale return pattern date competition marketing matter specifically investigate analyze accounting sale return accrual sale return allowance represent reserve product return expiration destruction field specific area product recall return reserve base historical return trend product market percent gross sale accordance company accounting policy company generally issue credit customer return good company sale return reserve account accordance gaap guidance revenue recognition right return exist sale return reserve record sale value sale return consumer pharmaceutical segment exclusively resalable sale return certain franchise medical device segment typically resalable material company infrequently exchange product inventory return product sale return reserve total company approximately annual net trade sale fiscal reporting year promotional program product list allowance cooperative advertising arrangement record year incur continue promotional program include coupon volumebase sale incentive program redemption cost consumer coupon base historical redemption experience product value volumebase incentive program base estimate sale volume incentive period record product sell company earn service revenue copromotion certain product year present service revenue total revenue include sale customer arrangement evaluate determine appropriate amount defer record reduction revenue addition company enter collaboration arrangement contain multiple revenue generating activity amount collaborative partner arrangement recognize activity perform deliver base relative fair value upfront fee receive arrangement defer recognize performance period note consolidated financial statement additional disclosure collaboration reasonably likely change assumption calculate accrual rebate return promotion anticipate material effect financial statement company currently disclose impact change assumption quarterly annual filing material financial statement impact table progression accrue rebate return promotion reserve doubtful account reserve cash discount segment business fiscal year end january december consumer segment balance begin balance dollar million period accrual paymentscredit end period accrue rebate accrue return accrue promotions subtotal reserve doubtful account reserve cash discount total accrue rebate accrue return accrue promotions subtotal reserve doubtful account reserve cash discount total include reserve customer rebate million january million december record contra asset pharmaceutical segment balance begin balance dollar million period accrual paymentscredit end period accrue rebate accrue return accrue promotions subtotal reserve doubtful account reserve cash discount total accrue rebate accrue return accrue promotions subtotal reserve doubtful account reserve cash discount total include reserve customer rebate million january million december record contra asset prior year reclassify conform current year presentation medical device segment balance begin balance dollar million period accrual paymentscredit end period accrue rebate accrue return accrue promotions subtotal reserve doubtful account reserve cash discount total accrue rebate accrue return accrue promotions subtotal reserve doubtful account reserve cash discount total include reserve customer rebate million january million december record contra asset income taxis income taxis record base amount refundable payable current year include result difference gaap accounting tax reporting record defer tax asset liability company estimate defer tax asset liability base enact tax regulation rate future change tax law rate affect record defer tax asset liability company unrecognize tax benefit uncertain tax position company follow gaap prescribe recognition threshold measurement attribute financial statement recognition measurement tax position take expect take tax return management believe change estimate material effect company result operation cash flow financial position january december cumulative amount undistribute international earning approximately billion billion respectively january december company foreign subsidiary hold balance cash cash equivalent marketable security amount billion billion respectively company provide defer taxis undistribute earning certain international subsidiary earning consider permanently reinveste company intend continue reinvest earning international operation company decide later date repatriate earning company require provide net tax effect amount company determine defer tax liability associate undistributed earning determination practical note consolidated financial statement information income taxis legal self insurance contingency company record accrual contingency include legal proceeding product liability claim arise normal course business accrual base management judgment probability loss applicable actuarially determined estimate company self insurance whollyowne captive insurance company addition accrual self insurance program claim exceed insurance coverage accrue loss probable amount reasonably estimate additionally company record insurance receivable amounts thirdparty insurer recovery probable appropriate reserve receivables record estimate amount collect thirdpartyinsurer company follow provision gaap recording litigation relate contingency liability record loss probable reasonably estimate good estimate loss range accrue estimate range well minimum accrue note consolidated financial statement information product liability legal proceeding longlive intangible asset company assess change economic condition make assumption estimate future cash flow evaluate value company property plant equipment goodwill intangible asset assumption estimate change time necessary company record impairment charge employee benefit plan company sponsor retirement pension plan include define benefit define contribution termination indemnity plan cover employee worldwide plan base assumption discount rate expect return plan asset mortality rate expect salary increase health care cost trend rate attrition rate note consolidated financial statement detail rate effect rate change health care cost trend companys result operation stock base compensation company recognize compensation expense associate issuance equity instrument employee service base type equity instrument fair value estimate date grant blackschole option valuation model combination blackschole option valuation model monte carlo valuation model expense financial statement service period input assumption determine fair value expect life expect volatility riskfree rate expect dividend yield performance share unit fair market value calculate component goal date grant fair value sale earning share goal performance share unit estimate date grant fair market value share time award discount dividend pay performance share unit vest period fair value relative total shareholder return goal performance share unit estimate date grant monte carlo valuation model note consolidated financial statement additional information new accounting pronouncement refer note consolidated financial statement recently adopt accounting pronouncement recently issue accounting pronouncement adopt january economic market factor company aware product environment decade policymaker consumer business express concern rise cost health care response concern company longstande policy pricing product responsibly period united states weight average compound annual growth rate company net price increase health care product prescription overthecounter drug hospital professional product consumer price index cpi company operate certain country economic condition continue present significant challenge company continue monitor situation appropriate action inflation rate continue effect worldwide economy consequently way company operate company account operation venezuela highly inflationary prior threeyear cumulative inflation rate surpass face increase cost company strive maintain profit margin cost reduction program productivity improvement periodic price increase venezuelan government establish alternative system offering foreign currency exchange company primarily utilize official government rate bolivar fuertes dollar prepare consolidated financial statement company apply settle outstanding dividend payable alternative foreign exchange rate result company apply alternative exchange rate translate certain transaction appropriate fourth quarter number company transaction conduct official rate decline prior quarter result company determine long likely outstanding net monetary asset settle official government rate bolivar fuerte dollar company record charge million revalue net monetary asset venezuela government alternative exchange rate simadi impair nonmonetary asset revaluation january company venezuelan subsidiary represent company consolidate asset liability continue uncertain economic condition venezuela possible additional charge record future additional charge expect material adverse effect company year result company continue business greece company closely monitor economic situation january company greek subsidiary represent company consolidate asset revenue respectively company expose fluctuation currency exchange rate change value dollar ascompare foreign currency company sale income expense increase decrease translation foreign sale approximately million income million company face worldwide health care change continue result pricing pressure include health care cost containment government legislation relate sale promotion reimbursement health care product change behavior spend pattern purchaser health care product service include delay medical procedure ration prescription medication reduce frequency physician visit forego health care insurance coverage result current global economic downturn continue impact company business company operate environment increasingly hostile intellectual property right firm file abbreviate new drug application biosimilar biological product application fda challenge coverage andor validity company patent seek market generic biosimilar form company key pharmaceutical product prior expiration applicable patent cover product event company successful defend patent claim challenge result lawsuit generic biosimilar version product issue introduce market result potential substantial market share revenue loss product result noncash impairment charge associate intangible asset risk competitor launch generic biosimilar version product issue follow regulatory approval valid patent place information discussion remicade relate case litigation filer abbreviate new drug application note consolidated financial statement legal proceeding johnson johnson certain subsidiary involve lawsuit claim product liability intellectual property commercial matter governmental investigation legal proceeding arise time time ordinary course business company record accrual loss contingency associate legal matter probable liability incur loss reasonably estimate company accrue certain litigation matter continue monitor related legal issue adjust accrual new information development accordance accounting standard codification asc litigation regulatory matter currently disclose loss probable reasonably possible company unable estimate possible loss range loss amount accrue amount accrue legal contingency result complex series judgment future event uncertainty rely heavily estimate assumption ability estimate judgment affect factor include damage seek proceeding unsubstantiated indeterminate scientific legal discovery commence complete proceeding early stage matter present legal uncertainty significant fact dispute numerous party involve company opinion base examination matter experience date discussion counsel ultimate outcome legal proceeding net liability accrue company balance sheet expect material adverse effect company financial position resolution increase accrual matter report period material adverse effect company result operation cash flow period note consolidated financial statement information legal proceeding common stock market price company common stock list new york stock exchange symbol jnj february record holders common stock company composite market price range johnson johnson common stock high low high low quarter second quarter quarter fourth quarter yearend close cautionary factor affect future result annual report contain forwardlooke statement forwardlooke statement relate strictly historical current fact anticipate result base management plan subject uncertainty forwardlooke statement identify use word plan expect anticipate estimate word similar meaning conjunction thing discussion future operation financial performance company strategy growth product development regulatory approval market position expenditure forwardlooke statement base current expectation future event company guarantee forwardlooke statement accurate company believe reasonable expectation assumption investor realize underlying assumption prove inaccurate know unknown risk uncertainty materialize actual result vary materially company expectation projection investor caution place undue reliance forwardlooke statement company undertake update forwardlooke statement result new information future event development risk uncertainty include limited economic factor interest rate currency exchange rate fluctuation competition include technological advance new product patent attain competitor challenge uncertainty inherent new product development include uncertainty clinical success obtain regulatory approval uncertainty commercial success new exist product challenge patent impact patent expiration ability company successfully execute strategic plan include restructure plan potential expect benefit opportunitie relate restructuring realize long realize expect significant adverse litigation government action include related product liability claim impact business combination divestiture market condition possibility ongoing share repurchase program suspend discontinue significant change customer relationship change behavior spend pattern financial distress purchaser health care product service change applicable law regulation include global health care reform trend health care cost containment increase scrutiny health care industry government agency financial instability international economy legal system sovereign risk manufacturing difficulty delay internally supply chain complex global supply chain increase regulatory requirement product efficacy safety concern result product recall regulatory action disruption natural disaster potential failure meet obligation compliance agreement government body discussion factor cause actual result differ materially expectation find report fiscal year end january include exhibit company note factor permit private security litigation reform act item quantitative qualitative disclosure market risk information call item incorporate reference item management discussion analysis result operation financial condition liquidity capital resource finance market risk report note summary significant accounting policy financial instrument note consolidated financial statement include item report item financial statement supplementary datum index audit consolidated financial statement consolidate balance sheet consolidate statement earning consolidate statement comprehensive income consolidate statement equity consolidate statement cash flow note consolidated financial statement report independent register public accounting firm management report internal control financial reporting johnson johnson subsidiaries consolidate balance sheet january december dollar million share share amount note asset current asset cash cash equivalent note marketable security note account receivable trade allowance doubtful account inventory note prepay expense receivables total current asset property plant equipment net note intangible asset net note goodwill note defer taxis income note asset total asset liability shareholder equity current liability loan note payable note account payable accrue liability accrue rebate return promotions accrue compensation employee relate obligation accrue taxis income note total current liability longterm debt note defer taxis income note employee relate obligation note liability total liability shareholder equity prefer stock par value authorize unissued share common stock par value share note authorize share issue share accumulate comprehensive income note retain earning common stock hold treasury cost note share share total shareholder equity total liability shareholder equity note consolidated financial statement johnson johnson subsidiaries consolidate statement earning dollar share million share amount note sale customer cost product sell gross profit selling marketing administrative expense research development expense inprocess research development interest income interest expense net portion capitalize note income expense net restructure note earning provision taxis income provision taxis income note net earning net earning share note basic diluted cash dividend share average share outstanding note basic diluted note consolidated financial statement johnson johnson subsidiaries consolidate statement comprehensive income dollar million note net earning comprehensive income loss net tax foreign currency translation security unrealize hold gain loss arise period reclassification earning net change employee benefit plan prior service cost amortization period prior service credit cost current year gain amortization period gain loss current year effect exchange rate net change derivative hedge unrealize gain loss arise period reclassification earning net change comprehensive income loss comprehensive income tax effect comprehensive income fiscal year end respectively security million million million employee benefit plan million million million derivative hedge million million million note consolidated financial statement johnson johnson subsidiaries consolidate statement equity dollar million note accumulate common stock treasury retain comprehensive issue stock total earning income balance december net earning cash dividend pay employee compensation stock option plan repurchase common stock comprehensive income loss net tax balance december net earning cash dividend pay employee compensation stock option plan repurchase common stock comprehensive income loss net tax balance december net earning cash dividend pay employee compensation stock option plan repurchase common stock comprehensive income loss net tax balance january note consolidated financial statement johnson johnson subsidiaries consolidate statement cash flow dollar million note cash flow operating activity net earning adjustment reconcile net earning cash flow operating activity depreciation amortization property intangible stock base compensation venezuela adjustment asset writedown net gain sale assetsbusinesse net gain equity investment transaction defer tax provision account receivable allowance change asset liability net effect acquisition divestiture increase account receivable increase inventory decreaseincrease account payable accrue liability decreaseincrease current noncurrent asset increasedecrease current noncurrent liability net cash flow operating activity cash flow invest activity addition property plant equipment proceed disposal assetsbusinesse net acquisition net cash acquire note purchase investment sale investment primarily intangible net cash investing activity cash flow financing activity dividend shareholder repurchase common stock proceed shortterm debt retirement shortterm debt proceed longterm debt retirement longterm debt proceed exercise stock optionsexcess tax benefit net cash financing activity effect exchange rate change cash cash equivalent decreaseincrease cash cash equivalent cash cash equivalent begin year note cash cash equivalent end year note supplemental cash flow datum cash pay year interest interest net capitalize income taxis supplemental schedule noncash investing financing activity treasury stock issue employee compensation stock option plan net cash proceed conversion debt acquisition fair value asset acquire fair value liability assume noncontrolle interest net cash pay acquisition note consolidated financial statement note consolidated financial statement summary significant accounting policy principle consolidation consolidated financial statement include account johnson johnson subsidiaries company intercompany account transaction eliminate description company business segment company approximately employee worldwide engage research development manufacture sale broad range product health care field company conduct business virtually country world primary focus product relate human health wellbee company organize business segment consumer pharmaceutical medical device consumer segment include broad range product baby care oral care skin care overthecounter pharmaceutical womens health wound care market product market general public sell retail outlet distributor world pharmaceutical segment focus therapeutic area include immunology infectious disease neuroscience oncology cardiovascular metabolic disease product segment distribute directly retailer wholesaler hospital health care professional prescription use medical device segment include broad range product orthopaedic surgery cardiovascular diabetes care vision care field distribute wholesaler hospital retailer principally professional field physician nurse hospital eye care professional clinic new accounting pronouncement recently adopt accounting pronouncement fiscal second quarter financial accounting standard board fasb issue accounting standard update practical expedient measurement date employer define benefit obligation plan asset update provide practical expedient option entity define benefit plan fiscal yearend coincide calendar monthend option allow entity elect measure define benefit plan asset obligation calendar monthend close fiscal yearend update effective company annual interim period begin december practical expedient elect entity require adopt prospective basis early adoption permit company elect adopt practical expedient measure define benefit plan election material impact company consolidate financial statement fiscal fourth quarter fasb issue accounting standard update income taxis balance sheet classification defer taxis simplify presentation defer income taxis amendment update require defer tax liability asset classify noncurrent classify statement financial position update require effective public company annual period begin december interim period annual period early application permit company elect early adopt standard retrospective basis consolidated balance sheet reclassification reduce current asset billion increase noncurrent asset billion reduce liability billion recently issue accounting standard adopt january fiscal quarter fasb issue accounting standard update recognition measurement financial asset financial liability amendment update supersede guidance classify equity security readily determinable fair value different category trade availableforsale require equity security measure fair value change fair value recognize net income standard amend financial reporting provide relevant information entitys equity investment reduce number item recognize comprehensive income update effective company annual period begin december interim period annual period company currently assess impact future adoption standard financial statement fiscal second quarter fasb issue accounting standard update simplifying presentation debt issuance cost update requires capitalize debt issuance cost present reduction carrying value debt instead classify deferred charge currently require update effective company forall annual interim period begin december require apply retroactively period present update material impact presentation company financial position fiscal second quarter fasb issue accounting standard update simplifying measurement inventory update require inventory measure low cost net realizable value net realizable value estimate selling price ordinary course business reasonably predictable cost completion disposal transportation update effective company annual interim period begin december amendment update apply prospectively early application permit begin interim annual reporting period update material impact presentation company financial position fiscal quarter fasb issue accounting standard update business combination simplify accounting measurementperiod adjustment amendment update require acquirer recognize adjustment provisional amount identify measurement period report period adjustment amount determine update effective company annual interim period begin december amendment update apply prospectively adjustment provisional amount occur effective date update early application permit financial statement issue update expect material impact company consolidate financial statement fiscal second quarter fasb issue accounting standard update revenue contract customer standard replace substantially current revenue recognition accounting guidance fiscal quarter fasb approve year deferral effective date adopt public company annual period interim reporting period begin december early adoption standard permit original effective date annual period interim reporting period begin december company currently assess impact future adoption standard financial statement fiscal second quarter fasb issue amend guidance accounting standard update development stage entity elimination certain financial reporting requirement include amendment variable interest entity guidance topic consolidation change current guidance require company determine consolidate entity base change consolidation analysis update consolidation analysis effective annual period interim reporting period begin december adoption standard expect material impact presentation company consolidated financial statement fiscal quarter fasb issue accounting standard update disclosure uncertainty entitys ability continue go concern standard require management evaluate annual interim reporting period condition event consider aggregate raise substantial doubt entitys ability continue go concern year date financial statement issue available issue substantial doubt raise additional disclosure management plan alleviate doubt require update effective annual period interim reporting period end december standard expect impact current disclosure financial statement cash equivalent company classify highly liquid investment state maturity month date purchase cash equivalent highly liquid investment state maturity great month date purchase current marketable security company policy make investment commercial institution investment grade credit rating company invest cash primarily reverse repurchase agreement rra government security obligation corporate debt security money market fund rra collateralized deposit form government security obligation value company record asset liability company permit sell repledge associate collateral company policy collateral equivalent credit rating company utilize party custodian manage exchange fund ensure collateral receive maintain value rra daily basis rra state maturity great month date purchase classify marketable securitiesinvestment investment classify hold maturity investment report amortize cost realize gain loss report earning investment classify availableforsale carry estimate fair value unrealize gain loss record component accumulate comprehensive income availableforsale security available current operation classify current asset management determine appropriate classification investment debt equity security time purchase reevaluate determination balance sheet date company periodically review investment equity security impairment adjust investment fair value decline market value deem temporary loss security consider temporary loss recognize earning property plant equipment depreciation property plant equipment state cost company utilize straightline method depreciation estimate useful life asset building building equipment year land leasehold improvement year machinery equipment year company capitalize certain computer software development cost include machinery equipment incur connection develop obtain computer software internal use capitalize software cost amortize estimate useful life software generally range year company review longlive asset assess recoverability undiscounted cash flow certain event change operate economic condition occur impairment assessment perform recoverability carrying value asset asset determine impair loss measure base difference asset fair value carry value quote market price available company estimate fair value discount value estimate future cash flow revenue recognition company recognize revenue product sale good ship deliver title risk loss pass customer provision certain rebate sale incentive trade promotion coupon product return discount customer account reduction sale period relate sale record product discount grant base term arrangement direct indirect market participant market condition include price charge competitor rebate include medicaid estimate base contractual term historical experience patient outcome trend analysis project market condition market serve company evaluate market condition product group product primarily analysis wholesaler thirdparty sellthrough market research datum internally generate information sale return generally estimate record base historical sale return information product exhibit unusual sale return pattern date competition marketing matter specifically investigate analyze accounting sale return accrual sale returns allowance represent reserve product return expiration destruction field specific area product recall return reserve base historical return trend product market percent gross sale accordance company accounting policy company generally issue credit customer return good company sale return reserve account accordance gaap guidance revenue recognition right return exist sale return reserve record sale value sale return consumer pharmaceutical segment exclusively resalable sale return certain franchise medical device segment typically resalable material company infrequently exchange product inventory return product sale return reserve total company approximately annual sale customer fiscal reporting year promotional program product list allowance cooperative advertising arrangement record year incur continue promotional program include coupon volumebase sale incentive program redemption cost consumer coupon base historical redemption experience product value volumebase incentive program base estimate sale volume incentive period record product sell company earn service revenue copromotion certain product include sale customer arrangement evaluate determine appropriate amount defer record reduction revenueshipping handling shipping handling cost incur million million million respectively include sell marketing administrative expense revenue receive shipping handle sale customer period present inventory inventory state low cost market determine firstin firstout method intangible asset goodwill authoritative literature gaap require goodwill intangible asset indefinite life assess annually impairment company complete annual impairment test fiscal fourth quarter future impairment test perform annually fiscal fourth quarter soon warrant purchase inprocess research development account indefinite live intangible asset underlie project complete point intangible asset account definite live intangible asset abandon point intangible asset write partially impair intangible asset finite useful life continue amortize useful life review impairment warrant economic condition note detail intangible asset goodwill financial instrument require gaap derivative instrument record balance sheet fair value fair value exit price receive sell asset pay transfer liability fair value marketbase measurement determine assumption market participant use price asset liability authoritative literature establish threelevel hierarchy prioritize input measure fair value level high priority level low change fair value derivative record period current earning comprehensive income depend derivative designate hedge transaction type hedge transaction company document relationship hedge item derivative overall risk management strategy include reason undertake hedge transaction enter derivative objective strategy minimize foreign currency exposure impact company financial performance protect company cash flow adverse movement foreign exchange rate ensure appropriateness financial instrument manage enterprise risk associate financial institution note additional information financial instrument product liability accrual product liability claim record undiscounted basis probable liability incur liability reasonably estimate base exist information actuarially determine estimate applicable accrual adjust periodically additional information available company accrue estimate legal defense cost need defend matter cost probable reasonably estimate result cost availability factor effective november company cease purchase thirdparty product liability insurance company self insurance whollyowne captive insurance company addition accrual self insurance program claim exceed insurance coverage accrue loss probable amount reasonably estimate base availability prior coverage receivables insurance recovery relate product liability claim record undiscounted basis probable recovery realize appropriate reserve receivables record estimate amount collect thirdparty insurer concentration credit risk global concentration credit risk respect trade account receivables continue limited large number customer globally adherence internal credit policy credit limit economic challenge italy spain greece portugal southern european region impact certain payment pattern historically long experience international market total net trade account receivable balance southern european region approximately billion january approximately billion december approximately billion january approximately billion december southern european region net trade account receivable balance relate company consumer vision care diabetes care business certain pharmaceutical medical device customer line historical collection pattern remain balance net trade account receivable southern european region negatively impact time payment certain government own support health care customer certain distributor pharmaceutical medical device local affiliate total net trade account receivable balance customerswere approximately billion january billion december company continue receive payment customer case late payment interest customer payment expect period time long year revenue trade receivable discount estimate period time collection allowance doubtful account increase customer immaterial date company continue work closely customer payment plan monitor economic situation appropriate action necessary research development research development expense expense incurred upfront milestone payment party connection research development collaboration expense incur point regulatory approval payment party subsequent regulatory approval capitalize amortize remain useful life relate product amount capitalize payment include intangible net accumulate amortization company enter collaborative arrangement typically pharmaceutical biotechnology company develop commercialize drug candidate intellectual property arrangement typically involve party active participant collaboration expose significant risk reward dependent commercial success activity collaboration usually involve activity party include research development marketing selling distribution collaboration require upfront milestone royalty profit share payment contingent occurrence certain future event link success asset development amount collaborative partner relate development activity generally reflect reduction research development expense performance contract development service central company operation general income statement presentation collaboration follow naturetype collaboration statement earning presentation thirdparty sale product sale customer royaltiesmilestone pay collaborative partner post cost product sell regulatory approval royalty receive collaborative partner income expense net upfront payment milestone pay collaborative partner research development expense preregulatory approval research development payment collaborative partner research development expense research development payment receive reduction research development expense collaborative partner milestone capitalize intangible asset amortize cost good sell useful life year present individual project represent great total annual consolidated research development expense company number product compound develop collaboration strategic partner include xarelto codevelope bayer healthcare imbruvica develop collaboration comarketed pharmacyclic llc abbvie company advertising cost associate advertising expense year incur include sell marketing administrative expense advertising expense worldwide comprise television radio print medium internet advertising billion billion billion respectively income taxis income taxis record base amount refundable payable current year include result difference gaap accounting tax reporting record defer tax asset liability company estimate defer tax asset liability base enact tax regulation rate future change tax law rate affect record defer tax asset liability future company unrecognize tax benefit uncertain tax position company follow gaap prescribe recognition threshold measurement attribute financial statement recognition measurement tax position take expect take tax return management believe change estimate material effect company result operation cash flow financial position january december cumulative amount undistribute international earning approximately billion billion respectively january december company foreign subsidiary hold balance cash cash equivalent marketable security amount billion billion respectively company provide defer taxis undistribute earning certain international subsidiary earning consider permanently reinveste company intend continue reinvest earning international operation company decide later date repatriate earning company require provide net tax effect amount company determine defer tax liability associate undistributed earning determination practical note consolidated financial statement information income taxis net earning share basic earning share compute divide net earning available common shareholder weight average number common share outstanding period dilute earning share reflect potential dilution occur security exercise convert common stock treasury stock method use estimate preparation consolidate financial statement conformity accounting principle generally accept require management estimate assumption affect amount report estimate accounting sale discount rebate allowance incentive product liability income taxis depreciation amortization employee benefit contingency intangible asset liability valuation actual result differ estimate company follow provision gaap recording litigation relate contingency liability record loss probable reasonably estimate good estimate loss range accrue estimate range well minimum accrue annual closing date company follow concept fiscal year end sunday nearest end month december normally fiscal year consist week year fiscal year consist week case case reclassification certain prior period amount reclassify conform current year presentation cash cash equivalent current marketable security end cash cash equivalent current marketable security comprise dollar million current carry unrecognized unrecognized estimate cash marketable gain loss fair value equivalent security cash security sovereign security reverse repurchase agreement reverse repurchase agreement corporate debt security money market fund time deposit carry unrealized estimate gain unrealized loss fair value security corporate debt security available sale total cash cash equivalent current marketable security dollar million current carry unrecognized unrecognized estimate cash marketable gain loss fair value equivalent security cash security sovereign security reverse repurchase agreement reverse repurchase agreement corporate debt security money market fund time deposit total cash cash equivalent current marketable security hold maturity investment report amortize cost realize gain loss report earning available sale security report fair value unrealize gain loss report net taxis comprehensive income fair value government security obligation corporate debt security estimate quote broker price significant observable input contractual maturity substantially available sale security year january company invest excess cash deposit major bank world highquality money market instrument company policy make investment commercial institution investment grade credit rating inventory end inventory comprise dollar million raw material supply good process finish good total inventory property plant equipment end property plant equipment cost accumulate depreciation dollar million land land improvement building build equipment machinery equipment construction progress total property plant equipment gross accumulate depreciation total property plant equipment net company capitalize interest expense cost construction facility equipment interest expense capitalize million million million respectively depreciation expense include amortization capitalize interest billion billion billion respectively retirement disposal property plant equipment cost relate amount accumulate depreciation amortization eliminate asset accumulate depreciation account respectively difference net asset value proceed record earning intangible asset goodwill end gross net amount intangible asset dollar million intangible asset definite life patent trademark gross accumulate amortization patent trademarks net customer relationship intangible gross accumulate amortization customer relationship intangible net intangible asset indefinite live trademark purchase inprocess research development total intangible asset indefinite live total intangible asset net goodwill january december allocate segment business follow dollar million consumer pharmaceutical med devices total goodwill december goodwill relate acquisition goodwill relate divestiture currency translationother goodwill december goodwill relate acquisition goodwill relate divestiture currency translationother goodwill january weight average amortization period patent trademark customer relationship intangible asset year year respectively amortization expense amortizable asset include cost product sell billion billion billion tax fiscal year end january december december respectively estimate amortization expense succeed year approximate billion tax year intangible asset writedown include income expense net note consolidated financial statement additional detail relate acquisition divestiture fair value measurement company use forward foreign exchange contract manage exposure variability cash flow primarily relate foreign exchange rate change future intercompany product thirdparty purchase material denominate foreign currency company use cross currency interest rate swap manage currency risk primarily relate borrowing type derivative designate cash flow hedge additionally company use interest rate swap instrument manage interest rate risk relate fix rate borrowing derivative treat fair value hedge company use forward foreign exchange contract designate net investment hedge additionally company use forward foreign exchange contract offset exposure certain foreign currency asset liabilitie forward foreign exchange contract designate hedge change fair value derivative recognize earning offset current earning effect relate foreign currency asset liability company enter derivative financial instrument trade speculative purpose contain credit risk relate contingent feature requirement post collateral company counterparty ongoing basis company monitor counterparty credit rating company consider credit nonperformance risk low company primarily enter agreement commercial institution investment grade credit rating refer table significant financial asset liability measure fair value contain footnote receivables payable commercial institution january company notional amount outstanding forward foreign exchange contract cross currency interest rate swap interest rate swap billion billion billion respectively derivative instrument record balance sheet fair value change fair value derivative record period current earning comprehensive income depend derivative designate hedge transaction type hedge transaction designation cash flow hedge entrance date derivative contract inception derivative expect highly effective change fair value derivative designate cash flow hedge highly effective record accumulate comprehensive income underlie transaction affect earning reclassify earning account hedge transaction gain loss associate interest rate swap change fair value hedge debt attributable change interest rate record interest expense period occur gain loss net investment hedge account currency translation account insignificant ongoing basis company assess derivative continue highly effective offset change hedge item derivative long expect highly effective hedge accounting discontinue hedge ineffectiveness include current period earning income expense net forward foreign exchange contract cross currency interest rate swap interest rate swap designate fair valuehedge hedge ineffectiveness include current period earning interest expense current reporting period hedge ineffectiveness associate interest rate swap material january balance defer net loss derivative include accumulate comprehensive income million aftertax additional information consolidated statement comprehensive income note company expect substantially amount relate forward foreign exchange contract reclassify earning month result transaction expect occur period maximum length time company hedge transaction exposure month exclude interest rate contract ultimately realize earning differ foreign exchange rate change realize gain loss ultimately determine actual exchange rate maturity derivative follow table summary activity relate derivative designate cash flow hedge fiscal year end january december gainloss reclassify gainloss recognize accumulate oci gainloss recognize dollar million accumulate oci income incomeexpense cash flow hedge income statement caption sale customer cost product sell research development expense interest incomeinterest expense net income expense net total amount show table net tax effective portion ineffective portion forward foreign exchange contract cross currency interest rate swap fiscal year end january december loss million gain million respectively recognize income expense net relate forward foreign exchange contract designate hedge instrument fair value exit price receive sell asset pay transfer liability fair value marketbase measurement determine assumption market participant use price asset liability authoritative literature establish threelevel hierarchy prioritize input measure fair value level hierarchy describe level high priority level low fair value derivative financial instrument forward foreign exchange contract interest rate contract aggregation currency future cash flow discount present value prevail market interest rate subsequently convert dollar current spot foreign exchange rate company believe fair value derivative instrument materially differ amount realize settlement maturity change fair value material effect company result operation cash flow financial position company hold equity investment classify level debt security classify level company significant financial asset liability require revised valuation standard recognize fair value follow level input measure fair value level quote price active market identical asset liability level significant observable input level significant unobservable input company significant financial asset liability measure fair value january december follow dollar million level level level total total derivative designate hedge instrument asset forward foreign exchange contract interest rate contract total liability forward foreign exchange contract interest rate contract total derivative designate hedge instrument asset forward foreign exchange contract liability forward foreign exchange contract available sale investment equity investment debt security asset liability classify level exception equity investment million classify level include million million noncurrent asset fiscal year end january december respectively include million million noncurrent liability fiscal year end january december respectively include cross currency interest rate swap interest rate swap classify noncurrent asset carry equity investment million million january december respectively unrealize gain million million january december respectively unrealize loss million million january december respectively classify current marketable security classify current asset classify account payable note financial asset liability hold carrying consolidate balance sheet borrowing component longterm debt follow effective effective rate rate dollar million note month libor frn note debenture note debenture note note euro euro note zero coupon convertible subordinated debenture debenture note note debenture note note gbp gbp note debenture note note debenture debenture note note subtotal current portion total longterm debt weight average effective rate translation rate january translation rate december excess fair value carry value debt billion billion fair value noncurrent debt estimate market price corroborate quote broker price significant observable input company access substantial source fund numerous bank worldwide september company secure new day credit facility total credit available company approximate billion expire onseptember interest charge borrowing credit line agreement base bid provide bank prime rate london interbank offer rate libor plus applicable margin commitment fee agreement material company continue access liquidity commercial paper market shortterm borrowing current portion longterm debt amount approximately billion end billion borrow commercial paper program remainder principally represent local borrowing international subsidiary aggregate maturity longterm obligation commence dollar million income taxis provision taxis income consist dollar million currently payable tax international taxis total currently payable defer taxis international taxis total defer provision taxis income comparison income tax expense statutory rate company effective tax rate follow dollar million international earning taxis income tax rate statutory rate international operation exclude ireland ireland puerto rico operation research orphan drug tax credit state local manufacturing deduction tax international income tax benefit assetbusiness disposal effective tax rate company subsidiary operate puerto rico tax incentive effective tax rate decrease compare primarily attributable increase taxable income low tax jurisdiction relative high tax jurisdiction tax benefit result restructure international affiliate additionally effective tax rate affect item mention belowthe increase effective tax rate compare attributable follow divestiture ortho clinical diagnostic business approximate effective tax rate litigation accrual low tax rate mix earning high tax jurisdiction primarily accrual additional year brand prescription drug fee tax deductible additional tax expense relate plan increase dividend current year foreign earning compare prior year increase effective tax rate partially offset tax benefit billion associate conor medsystem divestiture effective tax rate reduce tax benefit associate writeoff asset tax purpose associate scios inc inclusion benefit research development tax credit control foreign corporation lookthrough provision provision enact law january retroactive january effective tax rate reduce company adjust unrecognized tax benefit result federal appeal court decision omj pharmaceutical inc litigation credit section internal revenue code note consolidated financial statement additional information settlement substantially issue relate company internal revenue service audit tax year impact settlement reflect tax international income line item reconciliation item note reflect key driver rate reconciliation temporary difference carryforward follow defer tax defer tax dollar million asset liability asset liability employee relate obligation stock base compensation depreciation nondeductible intangible international capitalize tax reserve liabilitie income report tax purpose net operating loss carryforward international miscellaneous international miscellaneous total deferred income taxis million net valuation allowance relate belgium million million net valuation allowance relate belgium million company whollyowne international subsidiary cumulative net loss company believe likely subsidiary realize future taxable income sufficient utilize defer tax asset follow table summarize activity relate unrecognized tax benefit dollar million begin year increase relate current year tax position increase relate prior period tax position decreases relate prior period tax position settlement lapse statute limitation end year unrecognize tax benefit billion january recognize affect company annual effective tax rate company conduct business file tax return numerous country currently tax audits progress number tax authority irs complete audit tax year currently audit tax year major jurisdiction company conduct business year remain open generally year company believe possible audits complete tax authority jurisdiction month company able provide reasonably reliable estimate time future tax payment relate uncertain tax position company classifie liability unrecognize tax benefit relate interest penalty longterm liabilitiesinterest expense penalty relate unrecognized tax benefit classify income tax expense company recognize tax interest expense million million million respectively total accrue interest million million respectively employee relate obligation end employee relate obligation record consolidated balance sheet dollar million pension benefit postretirement benefit postemployment benefit defer compensation total employee obligation current benefit payable employee relate obligation noncurrent prepay employee relate obligation million million respectively include asset consolidate balance sheet pension benefit plan company sponsor retirement pension plan include define benefit define contribution termination indemnity plan cover employee worldwide company provide postretirement benefit primarily health care eligible retire employee dependent international employee cover governmentsponsored program cost company significant retirement plan benefit employee hire january primarily base employee compensation year retirement number year service company announce define benefit plan amend adopt new benefit formula effective employee hire january benefit calculate new formula base employee compensation total year service international subsidiary plan fund deposit trustee annuity purchase group contract reserve provide company fund retiree health care benefit advance right modify plan future describe note consolidated financial statement company elect early adopt practical expedient begin fiscal year end measure define benefit plan calendar month end close fiscal year end company december december respectively measurement date international retirement benefit plan net periodic benefit cost company define benefit retirement plan benefit plan include follow component retirement plan benefit plan dollar million service cost interest cost expect return plan asset amortization prior service cost credit amortization net transition obligation recognize actuarial loss curtailment settlement net periodic benefit cost amount expect recognize net periodic benefit cost come year company define benefit retirement plan postretirement plan dollar million amortization net transition obligation amortization net actuarial loss amortization prior service credit unrecognized gain loss pension plan amortize average remain future service plan plan active employee amortize average life expectancy amortization gain loss benefit plan determine corridor great market value asset accumulate postretirement benefit obligation total unamortized gain loss excess corridor amortize average remain future service prior service costsbenefit pension plan amortize average remain future service plan participant time plan amendment prior service costbenefit benefit plan amortize average remain service eligibility age plan participant time plan amendment follow table represent weightedaverage actuarial assumption retirement plan benefit plan worldwide benefit plan net periodic benefit cost discount rate rate increase compensation level expect longterm rate return plan asset benefit obligation discount rate rate increase compensation level company discount rate determine consider current yield curve represent high quality longterm fix income instrument result discount rate consistent duration plan liabilitie fiscal year company change methodology determine service interest cost single weight average discount rate approach duration specific spot rate yield curve plan liability cash flow management conclude precise estimate prior change methodology company measure service interest cost utilize single weightedaverage discount rate derive yield curve measure plan obligation company account change change accounting estimate accordingly account prospective basis change impact benefit obligation material impact year result expect rate return plan asset assumption represent company assessment longterm return diversify investment portfolio globally assessment determine projection external financial source longterm historical average actual return asset class asset class allocation market measurement retirement benefit obligation mortality assumption update newly establish mortality table result increase project benefit obligationthe follow table display assume health care cost trend rate individual health care plan health care cost trend rate assume year rate cost trend rate assume decline ultimate trend year rate reach ultimate trend rate onepercentagepoint change assume health care cost trend rate follow effect onepercentage onepercentage dollar million point increase point decrease health care plan total interest service cost postretirement benefit obligation follow table set forth information relate benefit obligation fair value plan asset yearend company define benefit retirement plan postretirement plan retirement plan benefit plan dollar million change benefit obligation project benefit obligation begin year service cost interest cost plan participant contribution amendment actuarial gain loss divestiture acquisition curtailment settlement restructure benefit pay plan effect exchange rate project benefit obligation end year change plan asset plan asset fair value begin year actual return plan asset company contribution plan participant contribution settlement divestiture acquisition benefit pay plan asset effect exchange rate plan asset fair value end year fund status end year amount recognize company balance sheet consist follow noncurrent asset current liability noncurrent liability total recognize consolidated balance sheet end year amount recognize accumulate comprehensive income consist follow net actuarial loss prior service cost credit unrecognized net transition obligation total tax effect accumulate benefit obligation end year retirement plan benefit plan dollar million amount recognize net periodic benefit cost comprehensive income net periodic benefit cost net actuarial gain loss amortization net actuarial loss prior service cost credit amortization prior service cost credit effect exchange rate total recognize comprehensive income tax total recognize net periodic benefit cost comprehensive income company plan continue fund qualified plan comply pension protection act international plan fund accordance local regulation additional discretionary contribution deem appropriate meet longterm obligation plan certain plan fund common practice funding provide economic benefit consequently company pension plan fund company contribute million million international pension plan respectively follow table display fund status company qualified nonqualified pension plan international fund unfunded pension plan december december respectively plan international plan qualified plan nonqualifie plan fund plan unfunded plan dollar million plan asset project benefit obligation accumulate benefit obligation fund status project benefit obligation accumulate benefit obligation plan accumulate benefit obligation excess plan asset accumulate benefit obligation project benefit obligation plan asset billion billion billion respectively end billion billion billion respectively end follow table display project future benefit payment companys retirement benefit plan dollar million project future benefit payment retirement plan benefit plan follow table display project future minimum contribution unfunded retirement plan amount include discretionary contribution company elect future dollar million project future contribution pension plan oversee local committee board responsible overall administration investment pension plan determine investment policy strategy goal committee board consider factor include local pension rule regulation local tax regulation availability investment vehicle separate account commingle account insurance fund etc funded status plan ratio active retiree duration liability relevant factor include diversification liquidity local market liquidity base currency majority company pension fund open new entrant expect ongoing plan permit investment primarily liquid andor list little reliance illiquid nontraditional investment hedge fund companys retirement plan asset allocation end target allocation follow percent target plan asset allocation worldwide retirement plan equity security debt security total plan asset determination fair value plan asset plan establish welldocumented process determine fair value fair value base quote market price available list price quote available fair value base model primarily use input marketbase independently source market parameter include yield curve interest rate volatilitie equity debt price foreign exchange rate credit curve plan believe valuation method appropriate consistent market participant use different methodology assumption determine fair value certain financial instrument result different estimate fair value report date valuation hierarchy authoritative literature establish threelevel hierarchy prioritize input measure fair value level hierarchy describe table level high priority level low financial instrument categorization valuation hierarchy base low level input significant fair value measurement follow description valuation methodology investment measure fair value shortterm investment cash quote shortterm instrument value closing price hold deposit custodian bank investment investment vehicle value net asset value nav provide administrator fund nav base value underlie asset own fund minus liability divide number share outstanding nav quote price market active classify level government agency security limit number investment value closing price report major market individual security trade quote price available active market investment classify level valuation hierarchy quote market price available specific security fair value estimate pricing model quote price security similar characteristic discount cash flow quote market price security available active market classify level debt instrument limit number investment value closing price report major market individual security trade quote price available active market investment classify level quote market price available specific security fair value estimate pricing model quote price security similar characteristic discount cash flow classify level level debt instrument price base unobservable input equity security common stock value closing price report major market individual security trade substantially common stock classify level valuation hierarchy commingle fund investment vehicle value nav provide fund administrator nav base value underlie asset own fund minus liability divide number share outstanding asset level category quote market price market active insurance contract instrument issue insurance company fair value base negotiate value underlie investment hold separate account portfolio consider credit worthiness issuer underlie investment government assetbacke fix income security general insurance contract classify level quote price observable input pricing asset asset represent primarily limit partnership real estate investment commercial loan commercial mortgage classify corporate debt asset exchange list actively trade classified level inactively trade asset classify level limited partnership represent investment private equity similar fund value general partner certain limited partnership asset value unobservable input classify level follow table set forth retirement plan investment measure fair value december december quote price significant active significant market observable unobservable identical asset input input level level level total asset dollar million shortterm investment fund government agency security debt instrument equity security commingle fund insurance contract asset investment fair value company benefit plan unfunded commingle fund level million million december december respectively fair value johnson johnson common stock directly hold plan asset million total plan asset december million total plan asset december level gain loss table set forth summary change fair value plan level asset year end december december debt equity commingle insurance total dollar million instrument security fund contract asset level balance december realize gain loss unrealize gain loss purchase sale issuance settlement net transfer inout exchange rate change balance december realize gain loss unrealize gain loss purchase sale issuance settlement net transfer inout exchange rate change balance december saving plan company voluntary saving plan design enhance exist retirement program cover eligible employee company match percentage employee contribution consistent provision plan heshe eligible total company match contribution plan million million million respectively capital treasury stock change treasury stock treasury stock amount million treasury stock share thousand share balance december employee compensation stock option plan repurchase common stock balance december employee compensation stock option plan repurchase common stock balance december employee compensation stock option plan repurchase common stock balance january aggregate share common stock issue approximately share end cash dividend pay share compare dividend share share october company announce board director approve share repurchase program authorize company purchase billion company share common stock repurchase program time limit suspend period discontinue time share acquire available general corporate purpose company intend finance share repurchase program available cash access capital market january billion repurchase program july company announce board director approve share repurchase program authorize company purchase billion company share common stock share repurchase program complete april accumulate comprehensive income component comprehensive income loss consist follow total gain accumulate foreign loss currency gainloss employee derivative comprehensive dollar million translation security benefit plan hedge income loss december net change december net change december net change january amount accumulate comprehensive income present net relate tax impact foreign currency translation adjust income taxis relate permanent investment international subsidiary additional detail comprehensive income consolidated statement comprehensive income detail reclassification accumulate comprehensive income gainloss security reclassification release income expense net employee benefit plan reclassification include net periodic benefit cost note additional detail gainloss derivative hedge reclassification earning record account hedge transaction note additional detail international currency translation translation subsidiary operate nonus dollar currency company determine local currency international subsidiary functional currency highly inflationary economy define compound cumulative rate inflation past year substantial portion cash flow local currency consolidate international subsidiary balance sheet currency effect record component accumulate comprehensive income equity account include result translate certain balance sheet asset liability current exchange rate account historical rate locate highly inflationary economy translation balance sheet account highly inflationary economy reflect operating result rollforward change foreign currency translation adjustment include note net currency transaction gain loss include income expense loss million million million respectively earning share follow reconciliation basic net earning share dilute net earning share fiscal year end january december december millions share amount basic net earning share average share outstanding basic potential share exercisable stock option plan share repurchase treasury stock method convertible debt share accelerate share repurchase program adjust average share outstanding diluted diluted net earning share dilute net earning share calculation include dilutive effect convertible debt offset relate reduction interest expense million aftertax year million year diluted net earning share calculation include share relate stock option exercise price option average market value company stock dilute net earning share calculation fiscal year end december include dilutive effect million share relate accelerated share repurchase program associate acquisition synthes inc fiscal year rental expense lease commitment rental space vehicle manufacture equipment office datum processing equipment operating lease approximately million million million respectively approximate minimum rental payment require operating lease initial remain noncancelable lease term excess year january dollar million total commitment capital lease significant common stock stock option plan stock compensation agreement january company stockbase compensation plan share outstanding contract company longterm incentive plan longterm incentive plan longterm incentive plan expire april option restrict share grant subsequent date longterm incentive plan longterm incentive plan company issue million share common stock plus share cancel expire forfeit issue longterm incentive plan subsequent april share available future grant longterm incentive plan million end compensation cost charge income plan million million million respectively total income tax benefit recognize income statement sharebase compensation cost million million million respectively total unrecognized compensation cost million million million respectively weight average period cost recognize year year year respectively sharebase compensation cost capitalize inventory insignificant period company settle employee benefit equity issuance treasury share treasury share replenish year number share settle employee benefit equity issuances stock option stock option expire year date grant vest service period range month year option grant average high low price company common stock new york stock exchange date grant fair value option award estimate date grant blackschole option valuation model use assumption note follow table grant expect volatility represent blend rate year daily historical average volatility rate week average imply volatility rate base atthemoney trade johnson johnson option life year grant expect volatility represent blend rate year weekly historical overall volatility rate week average imply volatility rate base atthemoney trade johnson johnson option life year grant historical datum determine expect life option riskfree rate base treasury yield curve effect time grant average fair value option grant respectively fair value estimate base weighted average assumption riskfree rate expect volatility expect life year expect dividend yield summary option activity plan january december december change year end date present aggregate weighted intrinsic average exercise value share thousand outstanding share price dollar million share december option grant option exercise option canceledforfeite share december option grant option exercise option canceledforfeite share december option grant option exercise option canceledforfeite share january total intrinsic value option exercise million million million respectively follow table summarize stock option outstanding exercisable january share thousand outstanding exercisable average average exercise price range option average life exercise price option exercise price average contractual life remain year stock option outstanding december december average life year average life year respectively stock option exercisable december december average price average price respectively restrict share unit performance share unit company grant restrict share unit vest service period range month year company grant performance share unit pay share johnson johnson common stock end threeyear performance period performance share unit vest vest tie completion service period range month year achievement threeyear period equallyweighte goal directly align help drive longterm total shareholder return operational sale adjust operational earning share relative total shareholder return number share actually earn end thethreeyear period vary base actual performance target number performance share unit grant summary restrict share unit performance share unit activity plan january present outstanding outstanding restricted share performance share thousand unit share unit share december grant issue canceledforfeite share december grant issue canceledforfeite share december grant issue canceledforfeite share january average fair value restrict share unit grant respectively fair market value date grant fair value restrict share unit discount dividend pay restricted share unit vest period fair value restrict share unit issue million million million respectively weight average fair value performance share unit grant calculate weighted average fair market value component goal date grant fair value sale earning share goal performance share unit estimate date grant fair market value share time award discount dividend pay performance share unit vest period fair value relative total shareholder return goal performance share unit estimate date grant monte carlo valuation model fair value performance share unit issue million million respectively performance share unit vest segment business geographic area sale customer dollar million consumer united states international total pharmaceutical united states international total medical devices united states international total worldwide total income tax identifiable asset dollar million consumer pharmaceutical medical device total expense allocate segment general corporate worldwide total addition property depreciation plant equipment amortization dollar million consumer pharmaceutical medical device segment total general corporate worldwide total sale customer longlive asset dollar millions united states europe western hemisphere exclude asiapacific africa segment total general corporate non longlived asset worldwide total note description segment company operate export sale significant company wholesaler distribute product segment represent approximately respectively total consolidated revenue company customer represent total revenue amount allocate segment include interest income expense noncontrolle interest general corporate income expense general corporate include cash cash equivalent marketable security medical device segment include restructure charge million intangible asset writedown million related acclarent synthe integration cost million million expense cost associate depuy asrtm hip program include million inprocess research development expense comprise million million pharmaceutical medical device segment respectively include net litigation expense million comprise million pharmaceutical segment million medical device segment include gain litigation settlement agreement guidant million medical device segment include gain billion divestiture cordis business pharmaceutical segment include gain million divestiture nucynta positive adjustment billion previous reserve estimate include manage medicaid rebate consumer segment include gain million divestiture splenda brand include net litigation expense million comprise million million million medical device pharmaceutical consumer segment respectively include million inprocess research development expense comprise million million pharmaceutical medical device segment respectively medical device segment include net gain million divestiture orthoclinical diagnostic business synthe integration cost million million expense cost associate depuy asrtm hip program pharmaceutical segment include additional year brand prescription drug fee million positive adjustment billion previous reserve estimate include million net litigation expense comprise million million medical device pharmaceutical segment respectively include million synthe integrationtransaction cost medical device segment include million inprocess research development expense comprise million million pharmaceutical medical device segment respectively medical device segment include million expense cost associate depuy asrtm hip program include million income relate adjustment comprise million million consumer pharmaceutical segment respectively longlive asset include property plant equipment net respectively intangible asset goodwill net respectively select quarterly financial datum unaudite select unaudited quarterly financial datum year summarize second fourth second fourth dollar million share datum quarter quarter quarter quarter quarter quarter quarter quarter segment sale customer consumer pharmaceutical medical device total sale gross profit earning provision taxis income net earning basic net earning share dilute net earning share quarter include net litigation gain million aftertax million beforetax million aftertax million beforetax cost associate depuy asrtm hip program second quarter include net litigation expense million aftertax million beforetax quarter include net litigation expense million aftertax million beforetax fourth quarter include restructure charge million aftertax million beforetax million aftertax million beforetax impairment inprocess research development synthe integration cost million aftertax million beforetax additionally fourth quarter include gain cordis divestiture quarter include synthe integration cost million aftertax million beforetax million tax benefit associate conor medsystem second quarter include litigation expense million aftertax million beforetax synthe integration cost million aftertax million beforetax quarter include additional year brand prescription drug fee million tax litigation expense million aftertax million beforetax synthe integration cost million aftertax million beforetax million aftertax million beforetax cost associate depuy asrtm hip program additionally fiscal quarter include net gain billion aftertax billion beforetax divestiture orthoclinical diagnostic business fourth quarter include litigation expense primarily relate product liability patent litigation million aftertax million beforetax synthe integration cost million aftertax million beforetax million aftertax million beforetax impairment inprocess research development business combination divestiture certain business acquire million cash million liability assume assumed liability primarily represent fair value contingent consideration million acquisition account acquisition method accordingly result operation include financial statement respective date acquisition acquisition primarily include limited privatelyheld biopharmaceutical company develop antithrombin antibody novira therapeutics inc privately hold clinicalstage biopharmaceutical company develop innovative therapy curative treatment chronic hepatitis virus infection excess purchase price estimate fair value tangible asset acquire amount million assign identifiable intangible asset residual record goodwill approximately million identify value iprd primarily associate acquisition limited novira therapeutics inc value iprd calculate cash flow projection discount inherent risk project iprd relate acquisition limited million associate recombinant human antibody develop mimic activity human antibody appear produce anticoagulated state predisposition bleed probability success factor reflect inherent clinical regulatory risk discount rate apply iprd relate acquisition novira therapeutics inc million associate lead candidate nvr investigational small molecule directacte antiviral oral administration patient hbv inhibit hbv core capsid protein probability success factor reflect inherent clinical regulatory risk discount rate apply certain business acquire million cash million liability assume acquisition account acquisition method accordingly result operation include financial statement respective date acquisition acquisition include covagen privatelyheld biopharmaceutical company specialize development multispecific protein therapeutic fynomab technology platform alios biopharma inc privatelyheld clinical stage biopharmaceutical company focus develop therapy viral disease orsltm electrolyte ready todrink brand jagdale industries ltd excess purchase price estimate fair value tangible asset acquire amount million assign identifiable intangible asset residual record goodwill approximately million identify value iprd associate acquisition covagen alios biopharma inc value iprd calculate cash flow projection discount inherent risk project iprd relate acquisition alios biopharma inc alios million associate alio lead compound orally administer antiviral therapy treatment infant respiratory syncytial virus rsv probability success factor reflect inherent clinical regulatory risk discount rate apply iprd relate acquisition covagen million associate covagen lead compound cova currently phase study psoriasis hold potential treatment broad range inflammatory disease include rheumatoid arthritis probability success factor reflect inherent clinical regulatory risk discount rate apply company record charge impairment iprd relate acquisition covagen certain business acquire million cash million liability assume acquisition account acquisition method accordingly result operation include financial statement respective date acquisition assume liability primarily represent fair value contingent consideration payable related acquisition aragon pharmaceuticals inc privatelyheld pharmaceutical discovery development company focus drug treat hormonallydriven cancer term agreement additional payment million pay future base reach predetermine milestone acquisition include flexible stenting solutions inc lead developer innovative flexible peripheral arterial venous biliary stent shanghai elsker mother baby ltd baby care company china aragon pharmaceuticals inc excess purchase price estimate fair value tangible asset acquire amount million assign identifiable intangible asset residual record goodwill approximately million identify value iprd primarily associate acquisition aragon pharmaceuticals inc iprd relate acquisition aragon pharmaceuticals inc million associate aragon androgen receptor antagonist program treatment hormonallydriven cancer value iprd calculate cash flow projection discount inherent risk project probability success factor range reflect inherent clinical regulatory risk discount rate apply company complete acquisition synthes inc purchase price billion cash stock connection acquisition synthes inc company enter accelerated share repurchase asr agreement company settle remain liability asr agreement company believe transactions asr agreement series relate internal transaction consummate tax efficient manner accordance applicable law possible internal revenue service assert contrary position challenge transaction tax perspective challenge total purchase price synthe share treat subject applicable tax approximately statutory rate company plus interest supplemental pro forma information accordance gaap standard relate business combination goodwill intangible asset provide impact aforementione acquisition material effect company result operation cash flow financial position company divestiture include cordis business cardinal health splenda brand heartland food product group license right nucynta tapentadol nucynta tapentadolextendedrelease tablet nucynta tapentadol oral solution pretax gain divestiture business approximately billion january asset hold sale material company divestiture include orthoclinical diagnostic business carlyle group brand reckitt benckiser group plc certain market benecol brand raisio plc pretax gain divestiture business approximately billion company complete divestiture orthoclinical diagnostic business carlyle group approximately billion company record pretax gain approximately billion orthoclinical diagnostic result include company medical device segment company divestiture include woman sanitary protection product canada caribbean energizer holdings inc rolaids chattem inc doribax rights shionogi sale certain consumer brand certain pharmaceutical product pretax gain divestiture business billion legal proceeding johnson johnson certain subsidiary involve lawsuit claim product liability intellectual property commercial matter governmental investigation legal proceeding arise time time ordinary course business company record accrual loss contingency associate legal matter probable liability incur loss reasonably estimate january company determine liability associate certain litigation matter probable reasonably estimate company accrue matter continue monitor related legal issue adjust accrual warrant base new information development accordance asc litigation regulatory matter discuss loss probable reasonably possible company unable estimate possible loss range loss amount accrue amount accrue legal contingency result complex series judgment future event uncertainty rely heavily estimate assumption ability estimate judgment affect factor include damage seek proceeding unsubstantiated indeterminate scientific legal discovery commence complete proceeding early stage matter present legal uncertainty significant fact dispute numerous party involve company opinion base examination matter experience date discussion counsel ultimate outcome legal proceeding net liability accrue company balance sheet expect material adverse effect company financial position resolution increase accrual matter report period material adverse effect company result operation cash flow period product liability certain subsidiary johnson johnson involve numerous product liability claim lawsuit involve multiple product claimant case seek substantial compensatory available punitive damage subsidiary believe substantial defense feasible predict ultimate outcome litigation company establish accrual product liability claim lawsuit compliance asc base currently available information case limited company accrue estimate legal defense cost need defend matter certain matter company accrue additional amount estimate cost associate settlement damage loss product liability accrual represent project product liability thousand claim world different litigation environment different fact pattern change accrual require future additional information available significant case include depuy asr acetabular system depuy asr hip resurfacing system pinnacle acetabular cup system pelvic mesh risperdal xarelto january united states approximately plaintiff direct claim pende lawsuit injury allegedly depuy asr acetabular system depuy asr hip resurfacing system respect pinnacle acetabular cup system respect pelvic mesh respect risperdal respect xarelto august depuy orthopaedics inc depuy announce worldwide voluntary recall asr acetabular system depuy asr hip resurfacing system hip replacement surgery claim personal injury beenmade depuy johnson johnson number pende lawsuit expect fluctuate certain lawsuit settle dismiss additional lawsuit file case file federal court united states organize multidistrict litigation united states district court northern district ohio litigation file country outside united states primarily united kingdom canada australia november depuy reach agreement courtappointe committee lawyer represent asr hip system plaintiff establish program settle claim eligible asr hip patient unite states surgery replace asr hips know revision surgery august settlement cover approximately patient february depuy reach additional agreement effectively extend exist settlement program asr hip patient revision surgery august prior february second agreement estimate cover approximately additional patient estimate cost agreement cover exist accrual settlement program expect bring close significant asr hip litigation activity united states lawsuit united states remain settlement program address litigation outside united states company continue receive information respect potential cost associate recall worldwide basis company establish accrual cost associate depuy asr hip program relate product liability litigation change accrual require future additional information available claim personal injury depuy johnson johnson relate depuy pinnacle acetabular cup system hip replacement surgery number pende product liability lawsuit continue increase company continue receive information respect potential cost anticipate number case case file federal court united states organize multidistrict litigation united states district court northern district texas litigation file country outside united states primarily united kingdom company establish accrual cover defense cost connection product liability litigation associate depuy pinnacle acetabular cup system change accrual require future additional information available claim personal injury ethicon inc ethicon johnson johnson arising ethicon pelvic mesh device treat stress urinary incontinence pelvic organ prolapse number pende product liability lawsuit continue increase company continue receive information respect potential cost anticipate number case case file federal court united states organize multidistrict litigation united states district court southern district west virginia addition class action individual personal injury case claim commence australia belgium canada england israel italy netherlands scotland venezuela seek damage allege injury result ethicon pelvic mesh device company establish accrual respect product liability litigation associate ethicon pelvic mesh product change accrual require future additional information available claim personal injury janssen pharmaceuticals inc johnson johnson arising use risperdal indicate treatment schizophrenia acute manic mixed episode associate bipolar disorder irritability associate autism relate compound number pende product liability lawsuit continue increase company continue receive information respect potential cost anticipate number case company establish accrual respect product liability litigation associate risperdal change accrual require future additional information available claim personal injury janssen pharmaceuticals inc johnson johnson arising use xarelto oral anticoagulant number pende product liability lawsuit continue increase company continue receive information respect potential cost anticipate number case case file federal court united states organize multidistrict litigation united states district court eastern district louisiana addition case file state court united states case consolidate state mass tort litigation philadelphia pennsylvania class action lawsuit file canada company establish accrual respect product liability litigation associate xarelto change accrual require future additional information availableintellectual property certain subsidiary johnson johnson subject time time legal proceeding claim relate patent trademark intellectual property matter arise business matter involve challenge coverage andor validity patent product allegation certain company product infringe patent party subsidiary believe substantial defense challenge allegation respect significant patent assurance outcome matter loss case adversely affect ability subsidiary sell product result loss sale loss market exclusivity require payment past damage future royalty result noncash impairment charge associate intangible asset significant matter describe medical device january tyco healthcare group tyco surgical corporation covidien plc file lawsuit ethicon endosurgery inc ees united states district court district connecticut allege ee harmonic shear infringe tyco patent case try july march court rule ees harmonic shear infringe tyco patent order ee pay damage approximately million decline order injunctive relief ee appeal december united states court appeals federal circuit reverse district court ruling find asserted claim invalid july tyco file motion review united states supreme court july covidien file patent infringement lawsuit ees united states district court district connecticut seek damage preliminary injunction allege ee new version harmonic scalpels harmonic ace shear harmonic ace shear infringe tyco patent assert previous case claim assert covidien case claim declare invalid december court appeal tyco case discuss november united states supreme court deny tyco petition review case dismiss november roche diagnostic operations inc roche file patent infringement lawsuit lifescan inc lifescan united states district court district delaware allege lifescan onetouch line blood glucose monitoring system infringe patent relate use microelectrode sensor roche seek monetary damage injunctive relief september lifescan obtain favorable rule claim construction preclude find infringement roche appeal court appeal reverse district court rule claim construction remand case district court new finding issue december district court rule lifescan favor reinstate original claim construction february roche appeal rule february oral argument take place court appeal party await decision june rembrandt vision technology rembrandt file patent infringement lawsuit johnson johnson vision care inc jjvc united states district court eastern district texas allege jjvc manufacture sale acuvueadvance acuvue oasys hydrogel contact lense infringe patent patent rembrandt seek monetary relief case transfer united states district court middle district florida jury return verdict hold accuse lense infringe patent rembrandt appeal august united states court appeal federal circuit affirm district court judgment rembrandt ask district court grant new trial base alleged new evidence july district court deny rembrandts motion rembrandt appeal district court denial motion new trial december state israel file lawsuit district court tel aviv jaffa omrix biopharmaceutical inc affiliate omrix lawsuit state claim employee governmentowned hospital inventor patent relate fibrin glue technology employee develop government employee state claim right transfer intellectual property omrix belong state state seek damage plus royalty quixil evicel product alternatively transfer patent state case remain active trial date set september lifescan inc lifescan file lawsuit shasta technologies llc shasta instacare corp pharmatech solutions inc pharmatech conductive technologies inc conductive united states district court northern district california patent infringement false advertising make marketing astrip use lifescan onetouch blood glucose meter defendant allege lifescan patentsinsuit invalid challenge validity assert patent united states patent trademark office uspto april defendant bring counterclaims allege antitrust violation false advertising claim stay pende resolution patent infringement case validity patent confirm uspto uspto determine patent patent patent invalid lifescan lose appeal decision seek rehear lifescan enter settlement agreement shasta conductive motion bring pharmatech summary judgment patent invalidity argue february party await decision lifescan patent infringement false advertising claim schedule try august lifescan file patent infringement lawsuit unistrip technologies llc unistrip united states district court district north carolina allege make marketing unistrip strip infringe patent assert shasta case stay pende outcome appeal uspto decision validity patent july unistrip bring lawsuit lifescan united states district court eastern district pennsylvania allege antitrust violation relate marketing practice lifescan strip march medinol ltd medinol file patent infringement lawsuit cordis corporation cordis johnson johnson united states district court southern district new york allege cordis sale cypher cypher select stent united states willfully infringe medinol patent direct geometry articulate stent medinol seek damage attorney fee trial january district court dismiss case find medinol unreasonably delay bring claim medinol appeal decision september district court deny motion medinol vacate judgment grant new trial medinol appeal decision dismiss medinol file petition review united states supreme court follow divestiture cordis company retain liability result case december bonutti skeletal innovation llc bonutti sue depuy synthes sales inc depuy synthes products inc united states district court district massachusetts allege depuy synthe product line spine implant infringe patent own bonutti generally cover wedge implant method implantation bonutti seek monetary damage injunctive relief pharmaceutical noramco inc noramco move intervene patent infringement lawsuit file united states district court southern district new york purdue pharma purdue noramco oxycodone customer impax laboratories inc impax teva pharmaceuticals usa inc teva amneal pharmaceuticals llc amneal watson laboratories inc florida watson andrx labs llc andrx lawsuit response defendant respective abbreviate new drug application seek approval market generic extend release oxycodone product expiration certain purdue patent asserted patent relate oxycodone process make oxycodone noramco agree defend lawsuit behalf impax teva amneal watson andrx april watson andrx enter settlement purdue trial impax teva take place september noramco defend teva impax november impax enter settlement purdue december teva enter settlement purdue district court issue decision january invalidate relevant purdue patent base decision subsequently dismiss lawsuit amneal party defend noramco purdue appeal court decision february federal circuit affirm district court decision invalidate purdue patent purdue ultimately prevail appeal invalidity decision reinstitute action amneal december purdue file patent infringement action amneal district delaware assert abovereference patent newly issue patent relate oxycodone process make oxycodone johnson johnson acquire prostate cancer business aragon pharmaceuticals inc aragon include arn compound test treatment prostate cancer september prior acquisition medivation inc medivation sue aragon university california seek right arn december state court grant summary judgment aragon medivation claim award right arn compound aragon january court dismiss case aragon medivation appeal remicade relate case september jbi nyu langone medical center nyu medical center receive office action united states patent trademark office uspto reject claim patent relate remicade patent reexamination proceeding institute party patent coowne jbi nyu medical center nyu medical center grant jbi exclusive license nyu medical center right patent currently patent united states expire september jbi respond rejection december august jbi nyu medical center receive rejection jbi respond rejection filing amendment november jbi petition enter amendment grant application return examiner issuance new office action occur february reject patent jbi respond rejection april uspto issue action maintain rejection patent jbi file notice appeal uspto patent trial appeal board appeal currently pende patent remain valid enforceable patent undergo reexamination uspto jbi continue defend patent necessary pursue available appeal august celltrion file fda approval sell biosimilar version remicade march jbi file lawsuit united states district court district massachusetts celltrion hospira seek declaratory judgment biosimilar product seek fda approval new biologic price competition innovation act bpcia infringe potentially infringe jbi patent jbi seek declaratory judgment defendant fail comply certain procedural requirement bpcia addition jbi move preliminary permanent injunction prohibit celltrion hospira launch biosimilar product day give jbi notice commercial marketing notice give fda approval celltrion product march jbi move stay proceeding district court respect patent pende uspto reexamination proceeding august jbi file motion seek district court permission file patent infringement lawsuit assert patent patent celltrion manufacturer cell culture medium celltrion use biosimilar product patent assert exist lawsuit expand claim include use cell medium united states manufacture celltrion biosimilar february celltrion hospira agree launch biosimilar product june patent remain patent lawsuit light representation federal circuit court appeal expect decide issue unrelated similar case june court deny jbi motion preliminary injunction note jbi renew motion follow court appeal decision necessary court appeal fail decide issue june addition february celltrion hospira file motion summary judgment invalidity patent march hospira healthcare corporation hospira file impeachment proceeding kennedy institute rheumatology kennedy challenge validity canadian patent relate remicade feldman patent exclusively license janssen biotech inc jbi october kennedy jbi janssen inc cilag gmbh international affiliates jbi file counterclaim infringement celltrion healthcare ltd celltrion inc celltrion hospira counterclaim allege product describe celltrion hospira marketing application health canada subsequent entry biologic seb remicade infringe feldman patent own kennedy discovery patent action ongoing trial schedule september january health canada approve celltrion seb remicade allow celltrion market biosimilar version remicade canada regardless pende patent action june hospira receive approval seb remicade july janssen inc janssen file lawsuit compel canadian minister health withdraw notice compliance hospira seb hospira serve notice allegation janssen address patent list janssen patent register march party enter settlement agreement health canada agree consent judgment set aside hospiras notice compliance subject health canada right appeal appeal file june hospira begin market biosimilar version remicade distributor celltrion notice compliance remicade relate patent discuss find invalid patent relied prevent introduction biosimilar version remicade biosimilar version remicade introduce certain market outside united states result reduction sale remicade market time possible introduction biosimilar version remicade united states subject enforcement ofpatent right approval fda compliance day notice provision bpcia february arthritis advisory committee fda recommend approval celltrion investigational biosimilar version remicade vote eligible indication united states risk competitor launch biosimilar version remicade follow fda approval subject compliance day notice provision bpcia valid patent place introduction market biosimilar version remicade result reduction sale remicade litigation filer abbreviate new drug application anda follow summarize lawsuit pende generic company file abbreviate new drug application andas fda undertake similar regulatory process outside united states seek market generic form product sell subsidiary johnson johnson prior expiration applicable patent cover product anda typically include allegation noninfringement invalidity unenforceability applicable patent event subsidiarie successful action statutory month stay andas expire united states district court ruling obtain thirdparty company involve ability approval fda introduce generic version product issue market result potential substantial market share revenue loss product result noncash impairment charge associate intangible asset addition time time subsidiary settle action settlement involve introduction generic version product issue market prior expiration relevant patent prezista number generic company file anda seek approval market generic version prezista november tibotec inc tibotec llc tibotec pharmaceutical janssen ireland collectively tibotec file patent infringement lawsuit lupin ltd lupin pharmaceuticals inc collectively lupin mylan inc mylan pharmaceuticals inc collectively mylan united states district court district new jersey response lupin mylan respective anda seek approval market generic version tibotec prezista product expiration tibotec patent relate prezista lupin mylan file counterclaim allege noninfringement invalidity july tibotec file patent infringement lawsuit lupin united states district court district new jersey response lupin supplement anda add new dosage strength propose product august tibotec searle company searle file patent infringement lawsuit lupin mylan response notice letter advise anda seek approval market generic version tibotec prezista product expiration additional patent relate prezista tibotec exclusively license searle september court consolidate lawsuit refer consolidated action approve new drug application prezista transfer tibotec inc janssen product december janssen product janssen ireland collectively janssen add patent exclusively license searle consolidated action mylan lupin june janssen searle dismiss claim relate patent own searle lupin mylan base party agreement seek fda approval respective andas november expiration searle patent trial remain patent consolidated action court issue decision august favor janssen holding assert patent valid infringe lupin mylan marketing propose product mylan lupin file appeal july janssen file patent infringement lawsuit mylan united states district court district new jersey allege infringement united states patent november janssen mylan enter confidential settlement pursuant settlement agreement party process seek dismissal action addition appeal august decision relate mylan dismiss remand district court party seek modification court order accordance settlement agreement lupin notify janssen file anda seek approval market new dosage strength generic version prezista response janssen file patent infringement lawsuit united states district court district new jersey allege lupin new dosage strength infringe patent janssen assert lupin original action march janssen file patent infringement lawsuit lupin united states district court district new jersey allege infringement united states patent patent january court consolidate lawsuit refer second consolidated action stay pende lupin appeal court decision consolidated action april lupin file inter parte review uspto seek invalidate patent october uspto deny lupin petition january janssen receive patent notice lupin advise lupin amend anda reflect new formulation darunavir lupin allege infringe relevant janssen patent february janssen file lawsuit assert patent lupin united states district court district new jersey addition january lupin file motion stay deactivate appeal abovereference august decision remand matter district court lupin intend modify district court order injunction allow lupin market new formulation darunavir expiration relevant patent janssen file patent infringement lawsuit hetero drugs ltd unit iii hetero usa inc march united states district court district new jersey allege infringement united states patent nos october party stipulate consent judgment hetero defendant admit patentsinsuit valid infringe manufacture importation use sale hetero anda product agree injunction respect product life patentsinsuit hetero reserve right develop noninfringe darunavir product process august janssen file patent infringement lawsuit cipla ltd cipla usa inc collectively cipla united states district court district new jersey delaware response ciplas anda seek approval market generic version janssen prezista product expiration certain janssen patent relate prezista cipla file counterclaim seek declaration noninfringement invalidity patentsinsuit janssen cipla enter settlement agreement response notice allegation seek approval market generic version prezista canada expiration canadian patent janssen inc janssen ireland file notice application mylan pharmaceuticals ulc july december janssen ireland transfer prezista patents janssen sciences ireland janssen sciences ireland substitute janssen ireland plaintiff reference action february party enter confidential settlement notice application dismiss january janssen inc janssen sciences ireland file notice application teva canada limited response notice allegation seek approval market generic version prezista expiration canadian patent october party enter settlement teva canada limited agree withdraw notice allegation prejudice file new future janssen inc janssen sciences ireland agree dismiss notice application lawsuit janssen seek seek order enjoin defendant market generic version prezista expiration relevant patent concerta alza corporation alza janssen pharmaceuticals inc jpi file patent infringement lawsuit united states district court district west virginia mylan inc mylan pharmaceuticals inc mylan response anda seek approval market generic version concerta expiration united states patent patent mylan file counterclaim seek declaration invalidity noninfringement patentsinsuit mylan seek leave add counterclaim invalidity noninfringement patent patent court deny mylan motion july mylan file declaratory judgment action eastern district pennsylvania seek declaration invalidity noninfringement patent october party enter confidential settlement west virginia pennsylvania action december janssen inc alza file notice application actavis pharma company actavis response notice allegation seek approval market generic version concerta expiration canadian patent patent hearing schedule september february janssen inc alza file notice application apotex inc apotex response notice allegation seek approval market generic version concerta expiration patent august janssen inc alza voluntarily dismiss notice applicationin lawsuit alza andor jpi seek seek order enjoin defendant market generic version concerta expiration relevant patent zytiga june july janssen biotech inc jbi receive notice paragraph certification company advise respective anda seek approval generic version zytiga expiration patent relate zytiga july jbi janssen oncology inc janssen research development llc collectively janssen btg international ltd btg file patent infringement lawsuit united states district court district new jersey generic anda applicant certain affiliate andor supplier response respective anda seek approval market generic version zytiga expiration united states patent nos patent expire december andor patent expiring august generic company include actavis laboratory inc actavis amneal pharmaceutical llc amneal pharmaceutical new york llc collectively amneal apotex inc apotex corp collectively apotex citron pharma llc citron reddys laboratories ltd reddys laboratories inc collectively reddy mylan pharmaceuticals inc mylan inc collectively mylan par pharmaceuticals inc par pharmaceutical companies inc collectively par sun pharmaceutical industries ltd sun pharmaceuticals industries inc collectively sun teva pharmaceuticals usa inc teva wockhardt bio wockhardt usa llc wockhardt ltd collectively wockhardt westward pharmaceutical corp westward hikma pharmaceuticals llc hikma court enter stay new jersey lawsuit par citron agree bind decision defendant new jersey action february new jersey court set trial date october august janssen btg file additional jurisdictional protective lawsuit mylan defendant united states district court northern district west virginia october mylan file motion dismiss new jersey lawsuit lack personal jurisdiction improper venue february west virginia court stay west virginia case pende decision mylan motion dismiss new jersey lawsuit set conditional trial date february court dismiss west virginia lawsuit mylan motion dismiss new jersey deny august jbi receive notice paragraph certification hetero usa inc regulatory agent hetero labs limited unitv division hetero labs limit collectively hetero advise hetero anda seek approval generic version zytiga expiration patent september janssen btg file amend complaint new jersey lawsuit allege infringement patent hetero filing abovereference lawsuit trigger stay october fda grant final approval generic anda early district court decision finding patentsinsuit invalid infringe december amerigen pharmaceutical limit file petition inter parte review uspto seek invalidate patent lawsuit janssen seek order enjoin defendant market generic version zytiga expiration relevant patent complera august september janssen pharmaceutica janssen sciences ireland collectively janssen gilead sciences inc gilead sciences ireland collectively gilead file patent infringement lawsuit united states district court district delaware west virginia mylan inc mylan pharmaceuticals inc collectively mylan response anda seek approval market generic version complera expiration united states patent nos september mylan file answer west virginia action include counterclaim seek declaration invalidity noninfringement patentsinsuit united states patent september mylan file motion dismiss delaware lawsuit lack personal jurisdiction january janssen gilead file amend complaint new jersey action add claim patent infringement respect united states patent nos addition new jersey action court dismiss mylan motion dismiss set trial date february west virginia action court set trial date december february mylan renew motion dismiss lack jurisdictionin lawsuit janssen seek order enjoin defendant market generic version complera expiration relevant patent xarelto number generic company file anda seek approval market generic version xarelto october janssen pharmaceuticals inc jpi bayer pharma bayer intellectual property gmbh collectively bayer file patent infringement lawsuit aurobindo pharma limited aurobindo pharma usa inc breckenridge pharmaceutical inc micro labs usa inc micro labs ltd mylan pharmaceuticals inc mylan inc prinston pharmaceutical inc sigmapharm laboratory llc torrent pharmaceuticals limited torrent pharma inc united states district court district delaware response party respective anda seek approval market generic version xarelto expiration bayers united states patent nos relate xarelto jpi exclusive licensee assert patent jpi seek order enjoin defendant market generic version xarelto expiration relevant patent november mylan move dismiss action december jpi bayer mylan stipulate agree dismiss claim mylan inc suspend briefing argument mylan motion dismiss pending appeal relate personal jurisdiction mylan pharmaceuticals inc district delaware january jpi bayer receive paragraph notice invagen pharmaceuticals inc invagen advise seek fda approval generic xarelto product expiration relevant patent february jpi bayer file patent infringement action invagen assert xarelto patent assert original case invagen case consolidate original case court set trial date march government proceeding like company pharmaceutical medical device industry johnson johnson certain subsidiary subject extensive regulation national state local government agency united states country operate result interaction government agency ongoing significant litigation bring investigation conduct government agency list possible criminal charge substantial fine andor civil penalty damage result government investigation litigation average wholesale price awp litigation johnson johnson pharmaceutical subsidiary awp defendant numerous pharmaceutical company defendant series lawsuit state federal court involve allegation pricing market certain pharmaceutical product amount fraudulent actionable conduct thing company allegedly report inflated average wholesale price awp drug issue payor allege awps calculate provider reimbursement level case federal action state action remove federal court consolidated pretrial purpose multidistrict litigation mdl united states district court district massachusetts plaintiff case include class private person entity pay portion purchase drug issue base awp state government entity medicaid payment drug issue base awp june trial merit mdl court dismiss claim plaintiff class awp defendant march court dismiss claim class awp defendant prejudice awp case bring attorney general proceed trial manufacturer state case certain subsidiary johnson johnson settle include case alaska settle april case pende illinois new jersey wisconsin utah case illinois new jersey wisconsin proceed trial utah claim bring attorney general dismiss court state appeal dismissal conclusion similar pende matter defendant awp case awp defendant bring attorney general commonwealth pennsylvania try commonwealth court court find commonwealth favor regard certain claim pennsylvania unfair trade practice consumer protection law utpl enter injunction award million restitution million civil penalty court find awp defendant favor commonwealth claim unjust enrichment misrepresentationfraud civil conspiracy certain commonwealth claim utpl jjawp defendant appeal commonwealth court utpl ruling june pennsylvania supreme court vacate judgment enter commonwealth court remand case proceeding remand january commonwealth court dismiss monetary award awp defendant march ruling appeal pennsylvania supreme court december pennsylvania supreme court affirm order commonwealth court dismiss monetary award awp defendant risperdal november johnson johnson subsidiary janssen pharmaceuticals inc jpi finalize previously disclose settlement agreement united states department justice fortyfive state resolve federal investigation state medicaid claim relate past promotional practice risperdal matter jpi settle allege consumer fraud claim connection sale marketing risperdal thirtysix state district columbia september addition action attorney general state bring action jpi relate sale marketing risperdal seek follow remedy reimbursement medicaid public fund risperdal prescription write offlabel use compensation treat citizen allege adverse reaction risperdal civil fine penalty violation state false claim act consumer fraud statute punitive damage relief relate alleged unfair business practice certain action seek injunctive relief relate promotion risperdal action claim bring state attorney general settle individually settlement describe case bring attorney general mississippi kentucky settle december admission wrongdoing jpi state case go judgment trial discuss attorney general west virginia commence lawsuit janssen pharmaceutica inc jpi base claim allege consumer fraud duragesic risperdal jpi find liable damage assess million jpi file appeal november west virginia supreme court appeal reverse trial court decision december attorney general west virginia dismiss case relate risperdal payment jpi settle case insofar related duragesic attorney general louisiana file multicount complaint janssen pharmaceutica inc jpi johnson johnson later add defendant case try october issue try jury johnson johnson jpi violate state medical assistance program integrity law act misrepresentation allegedly mailing november dear health care professional letter risperdal jury return verdict jpi johnson johnson violate act award million damage trial judge subsequently award attorney general counsel fee expense million january louisiana supreme court reverse district court judgment favor attorney general render judgment favor johnson johnson jpi april louisiana supreme court deny attorney general petition seek rehear appellate argument result final dismissal case office general counsel commonwealth pennsylvania file lawsuit janssen pharmaceutica inc jpi multicount complaint relate janssen pharmaceutica sale risperdal commonwealth medicaid program trial occur june trial judge dismiss case close plaintiff evidence commonwealth file appeal july pennsylvania appeals court uphold dismissal commonwealth case attorney general south carolina file lawsuit johnson johnson janssen pharmaceutica inc jpi count march matter try jury liability time lawsuit limit claim violation south carolina unfair trade practice act include question johnson johnson jpi engage unfair deceptive act practice conduct trade commerce distribute november dear health care professional letter risperdal use product fdaapprove label jury find favor johnson johnson jpi june court award civil penalty approximately million jpi jpi appeal judgment february south carolina supreme court affirm trial court decision reverse remand case trial court net effect decision reduce judgment approximately million plus interest fiscal quarter company accrue million march jpi file petition rehear july south carolina supreme court grant petition file substitute opinion new opinion reduce judgment approximately million approximately million january united states supreme court deny jpi request review put end casein april lawsuit bring attorney general arkansas jury find jpi johnson johnson court impose penalty approximately billion january trial court award attorney fee approximately million jpi johnson johnson appeal award arkansas supreme court march arkansas supreme court dismiss state claim arkansas medicaid fraud false claim act approximately billion penalty reverse remand claim arkansas deceptive trade practice act april arkansas supreme court reject petition state rehearing case matter settle million mcneil consumer healthcare start june mcneil consumer healthcare division mcneilppc inc johnson johnson consumer inc mcneil consumer healthcare division mcneil consumer healthcare certain affiliate include johnson johnson company receive grand jury subpoenas united states attorney office eastern district pennsylvania request document broadly relate recall product mcneil consumer healthcare fda inspections fort washington pennsylvania lancaster pennsylvania manufacture facility certain document relate recall small number product subsidiary addition february government serve mcneilppc inc mcneilppc civil investigative demand seek record relevant investigation determine violation federal false claim act march mcneilppc enter guilty plea united states district court eastern district pennsylvania misdemeanor violation food drug cosmetic act mcneil ppc agree pay million fine million forfeiture resolve matter company receive civil investigative demand multiple state attorney general office broadly relate mcneil recall issue company continue cooperate inquiry coordinate multistate coalition resolution reach multistate coalition possible individual state attorney general office file civil monetary claim company january oregon attorney general file civil complaint johnson johnson mcneilppc mcneil healthcare llc state court allege civil violation oregon unlawful trade practice act relate early recall mcneil otc product november state court grant motion company dismiss oregon complaint entirety prejudice oregon appeal decision november court appeal state oregon reverse trial court reinstate oregon consumer protection claim december company file petition review oregon supreme court opioid litigation pharmaceutical company johnson johnson janssen pharmaceuticals inc jpi name lawsuit allege claim relate marketing opioid include duragesicnucynta nucynta santa clara orange counties california county file complaint state court orange county california numerous pharmaceutical manufacturer include jpi allege claim relate opioid marketing practice include false advertising unfair competition public nuisance county seek injunctive monetary relief february defendant file motion challenge sufficiency complaint august court stay case fda conclude ongoing inquiry safety effectiveness longterm opioid treatment june city chicago file complaint cook county circuit court group pharmaceutical manufacturer include jpi allege number claim relate opioid marketing practice include consumer fraud violation false claim seek injunctive monetary relief case later remove united states district court northern district illinois december jpi file motion dismiss city chicago amend complaint failure state claim november jpi file motion dismiss city chicago second amend complaint failure state claim september tennessee attorney general division consumer affair issue request information jpi pharmaceutical company relate opioids marketing practice august new hampshire attorney general consumer protection antitrust bureau issue subpoena jpi pharmaceutical company relate opioids marketing practice jpi object private contingent fee counsel participation investigation state behalf october state move enforce subpoenain december state mississippi file complaint chancery court judicial district hind county group pharmaceutical manufacturer include jpi allege number claim relate opioid marketing practice state mississippi seek penalty injunctive monetary relief september synthes inc synthe receive civil investigative demand issue pursuant false claim act united states attorney office eastern district pennsylvania demand seek information allegation fellowship offer hospital exchange agreement purchase product synthe produce document information response demand cooperate inquiry acclarent inc acclarent receive subpoena united states attorney office district massachusetts request document broadly relate sale marketing allege offlabel promotion acclarent relieva stratus microflow spacer product stratus spacer april indictment file united states district court district massachusetts charge presidentceo vice president sale acclarent acclarent officer indictment charge acclarent officer violation relate offlabel promotion stratus spacer allegation acclarent officer relate development sale marketing stratus spacer action allegedly take acclarent officer connection acquisition acclarent ethicon inc charge acclarent ethicon inc johnson johnson august depuy orthopaedics inc depuy inc depuy synthes inc johnson johnson services inc company receive informal request united states attorney office district massachusetts civil division united states department justice united states production material relate asr hip device july united states notify united states district court district massachusetts decline intervene qui tam case file pursuant false claim act company district court issue order august publicly unseal united states declination notice complaint matter remain seal addition october group state attorney general issue civil investigative demand relate development sale market depuy orthopaedic inc hip product july oregon department justice investigate matter independently state announce settlement asr hip device investigation total payment million state oregon october johnson johnson contact california attorney general office multistate attorney general investigation market surgical mesh product hernia urogynecological purpose johnson johnson subsidiary ethicon inc ethicon johnson johnson ethicon enter series tolling agreement state district columbia participate multistate investigation respond civil investigative demand serve certain participate state state seek monetary injunctive relief december therakos inc therakos subsidiary johnson johnson orthoclinical diagnostics inc ocd franchise receive letter civil division united states attorney office eastern district pennsylvania inform therakos united states attorney office investigate sale marketing uvadex methoxsalen uvar xts system period present united states attorney office request ocd johnson johnson preserve document relate investigation therakos subsequently acquire affiliate gore capital partner iii january ocd johnson johnson retain certain liability result investigation activity occur prior sale therakos march united states attorney office request johnson johnson produce certain document johnson johnson cooperate request follow divestiture ocd johnson johnson retain ocds portion liability result investigation activity occur prior sale therakos recent year johnson johnson receive numerous request variety united states congressional committee produce information relevant ongoing congressional inquiry policy johnson johnson cooperate inquiry produce request informationgeneral litigation september johnson johnson file lawsuit guidant corporation guidant united states district court southern district new york allege guidant breach provision merger agreement johnson johnson guidant june guidant file motion summary judgment july judge deny guidants motion trial conclude january february decision issue court johnson johnson guidant enter settlement agreement pursuant guidant agree pay johnson johnson million agree sue johnson johnson affiliates patent infringement certain stent product johnson johnson dismiss action guidant prejudice company record gain associate transaction fiscal quarter june follow public announcement orthoclinical diagnostics inc ocd receive grand jury subpoena united states department justice antitrust division connection investigation closed multiple class action complaint file ocd direct purchaser seek damage allege price fixing case consolidated pretrial purpose united states district court eastern district pennsylvania blood reagent antitrust litigation follow divestiture ocd johnson johnson retain liability result case august district court grant motion file plaintiff class certification april united states court appeal circuit reverse class certification ruling remand case district court proceeding october district court grant motion plaintiff class certification september johnson johnson johnson johnson inc mcneil consumer healthcare division johnson johnson inc receive notice civil claim file nick field supreme court british columbia canada civil claim civil claim putative class action bring behalf person reside british columbia purchase period september december mcneil infant child overthecounter medicine manufacture fort washington facility civil claim allege defendant violate business practice consumer protection act canadian statute common law sell medicine allegedly safe andor effective comply canadian good manufacturing practice class certification hearing schedule october adjourn currently date set hearing august united states customs border protection cbp issue penalty notice janssen ortho llc janssen ortho assess penalty allege improper classification darunavir ethanolate prezista connection importation united states october janssen ortho submit petition relief response penalty notice cbp issue amend penalty notice assess substantial penalty janssen ortho file petition relief july march costco wholesale corporation costco file complaint johnson johnson vision care inc jjvci united states district court northern district california allege antitrust claim unlawful vertical price fixing agreement jjvci costco unnamed distributor retailer costco allege allege agreement harm competition cause increase price costco customer pay jjvci contact lense costco seek injunction monetary damage june case transfer united states district court middle district florida relate class action case describe november court deny jjvci motion dismiss march april putative class action complaint file contact lens patient number court united states johnson johnson vision care inc jjvci contact lens manufacturer distributor retailer allege vertical horizontal conspiracy fix retail price contact lense complaint allege manufacturer reach agreement certain distributor retailer concern price contact lense sold consumer plaintiff seek damage class action case transfer united states district court middle district florida june relate case file costco wholesale corporation describe plaintiff file consolidated class action complaint november december jjvci defendant file motion dismiss april johnson johnson vision care inc jjvci file complaint united states district court district utah state utah seek declaratory judgment law pass state ban unilateral pricingpolicie solely contact lens market violate commerce clause united states constitution court deny jjvci motion preliminary injunction jjvci appeal argument appeal hold august april adimmune corporation ltd adimmune commence arbitration international court arbitration international chamber commerce crucell switzerland janssen vaccines crucell holland collectively crucell adimmune claim crucell breach certain agreement relate supply flu antigen crucell cease purchasing flu antigen adimmune december adimmune file statement claim seek monetary damage august thirdparty payor file purport class action united states district court eastern district louisiana janssen research development llc janssen ortho llc janssen pharmaceuticals inc ortho mcneiljanssen pharmaceuticals johnson johnson certain bayer entity allege defendant improperly market promote xarelto safe effective expensive alternative medication fail fully disclose risk complaint seek damage unspecified johnson johnson subsidiary party number proceeding bring comprehensive environmental response compensation liability act commonly know superfund comparable state local foreign law primary relief seek cost past andor future remediation restructure company announce restructuring action medical device segment well serve need patient customer todays evolve healthcare marketplace company undertaking action strengthen gotomarket model accelerate pace innovation prioritize key platform geography streamline operation maintain high quality standard company estimate connection plan record pretax restructuring charge approximately billion billion expect incur fiscal fourth quarter company record pretax charge million million include cost product sell million restructuring charge consist severance cost million asset writeoff million million cost primarily relate supply contract additionally plan company expect restructuring action result position elimination approximately percent medical device segment global workforce year subject consultation procedure country require company estimate approximately half cumulative pretax cost result cash outlay include approximately million employee severance approximately half cumulative pretax cost noncash relate primarily facility rationalization inventory writeoff intangible asset writeoff follow table summarize severance charge associate spend fiscal year end dollar million severance asset writeoff total restructure charge current year activity reserve balance january cash outlay severance expect substantially pay month accordance company plan local law report independent register public accounting firm shareholder board directors johnson johnson opinion accompany consolidated balance sheet relate consolidated statement earning statement comprehensive income statement equity statement cash flow present fairly material respect financial position johnson johnson subsidiaries january december result operation cash flow year period end january conformity accounting principle generally accept united states america opinion company maintain material respect effective internal control financial reporting january base criterion establish internal control integrate framework issue committee sponsor organization treadway commission coso company management responsible financial statement maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include accompany management report internal control financial reporting responsibility express opinion financial statement company internal control financial reporting base integrated audits conduct audits accordance standard public company accounting oversight board united states standard require plan perform audits obtain reasonable assurance financial statement free material misstatement effective internal control financial reporting maintain material respect audits financial statement include examine test basis evidence support amount disclosure financial statement assess accounting principle significant estimate management evaluate overall financial statement presentation audit internal control financial reporting include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk audits include perform procedure consider necessary circumstance believe audits provide reasonable basis opinion discuss note consolidated financial statement company change manner classifie defer tax asset liabilitie company internal control financial reporting process design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle company internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition assets company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company iii provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate pricewaterhousecooper llp pricewaterhousecooper llp florham park new jersey february managements report internal control financial reporting section sarbanesoxley act management require assess effectiveness company internal control financial reporting end fiscal year report base assessment company internal control financial report effective management company responsible establish maintain adequate internal control financial reporting company internal control financial reporting design provide reasonable assurance reliability company financial reporting preparation external financial statement accordance generally accept accounting principle internal control financial reporting matter design inherent limitation internal control financial reporting determine effective provide reasonable assurance respect financial statement preparation prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate company management assess effectiveness company internal control financial reporting january make assessment company criterion establish committee sponsor organization treadway commission coso internal controlintegrate framework criterion area control environment risk assessment control activity information communication monitoring company assessment include extensive documenting evaluating testing design operating effectiveness internal control financial reporting base company process assessment describe management conclude january companys internal control financial report effective effectiveness company internal control financial reporting january audit pricewaterhousecooper llp independent register public accounting firm state report appear alex gorsky dominic caruso alex gorsky dominic caruso chairman board directors vice president finance chief executive officer chief financial officer shareholder return performance graph set forth line graph compare cumulative total shareholder return company common stock period year year end december cumulative total return standard poor stock index standard poors pharmaceutical index standard poors health care equipment index graph table assume invest december december company common stock standard poor stock index standard poors pharmaceutical index standard poors health care equipment index dividend reinveste year shareholder return performance indices johnson johnson index pharmaceutical index healthcare equipment index year shareholder return performance indices johnson johnson index pharmaceutical index healthcare equipment index item change disagreement accountant account financial disclosure applicable item control procedure disclosure control procedure end period cover report company evaluate effectiveness design operation disclosure control procedure company disclosure control procedure design ensure information require disclose company report file submit exchange act record process summarize report time period specify sec rule form disclosure control procedure include limitation control procedure design ensure information require disclose company report file submit exchange act accumulate communicate company management include principal executive principal financial officer person perform similar function appropriate allow timely decision require disclosure alex gorsky chairman chief executive officer dominic caruso vice president finance chief financial officer review participate evaluation base evaluation messr gorsky caruso conclude end period cover report company disclosure control procedure effective report internal control financial reporting information call item incorporate reference management report internal control financial reporting attestation internal control financial reporting include report independent register public accounting firm include item report change internal control financial reporting fiscal quarter end january change companys internal control financial reporting identify connection evaluation require rules exchange act materially affect reasonably likely materially affect company internal control financial reporting company implement multiyear enterprisewide initiative integrate simplify standardize process system human resource information technology procurement supply chain finance function enhancement support growth company financial share service capability standardize financial system initiative response identify deficiency weakness company internal control financial reporting response initiative company continue align streamline design operation financial control environment item information applicable iii item director executive officer corporate governance information call item incorporate reference discussion audit committee caption corporate governance board committee material caption item election director stock ownership section compliance section beneficial ownership report compliance proxy statement material caption executive officer registrant report company code business conduct cover employee include chief executive officer chief financial officer controller meet requirement sec rules promulgate section sarbanesoxley act code business conduct available company website wwwinvestorjnjcomgov policiescfm copy available shareholder charge write request secretary company principal executive office substantive amendment code business conduct waiver code grant chief executive officer chief financial officer controller post company website wwwinvestorjnjcomgovcfm business day retain website year addition company adopt code business conduct ethic member board director executive officer code business conduct ethic member board director executive officer available company website wwwinvestorjnjcomgovpoliciescfm copy available shareholder charge write request secretary company principal executive office substantive amendment thecode waiver code grant member board director executive officer post company website wwwinvestorjnjcomgovcfm business day retain website year item executive compensation information call item incorporate reference material caption item election director director compensation fiscal compensation committee report compensation discussion analysis executive compensation table proxy statement material incorporate reference material caption compensation committee report proxy statement shall deem furnish file report shall deem incorporate reference filing security act amend securities exchange act amend result furnish extent company specifically incorporate reference item security ownership certain beneficial owner management relate stockholder matter information call item incorporate reference material caption stock ownership section compliance proxy statement note common stock stock option plan stock compensation agreement note consolidated financial statement item report equity compensation plan information follow table provide certain information january concern share company common stock issue exist equity compensation plan number security weighted issue average exercise exercise price number security outstanding outstanding remain available option option future issuance equity plan category right right compensation plan equity compensation plan approve security holder equity compensation plan approve security holder total include category follow equity compensation plan approve company shareholder longterm incentive plan longterm incentive plan column exclude share reflect column number security issue exercise outstanding option right longterm incentive plan expire april option restrict share grant subsequent date longterm incentive plan item certain relationship relate transaction director independence information call item incorporate reference material caption corporate governance director independence relate party transaction proxy statement item principal accountant fee service information call item incorporate reference material caption ratification appointment independent register public accounting firm proxy statement item exhibit financial statement schedule follow document file report financial statement consolidate balance sheet end fiscal year consolidated statement earning fiscal year consolidate statement comprehensive income fiscal year consolidated statement equity fiscal year consolidated statement cash flow fiscal year note consolidated financial statement report independent register public accounting firm schedule omit applicable require information include financial statement note exhibit require file item regulation information call item incorporate reference exhibit index report signature pursuant requirement section securities exchange act registrant duly cause report sign behalf undersigned thereunto duly authorize date february johnson johnson registrant gorsky gorsky chairman board director chief executive officer pursuant requirement securities exchange act report sign follow person behalf registrant capacity date indicate signature title date gorsky chairman board director february gorsky chief executive officer director principal executive officer caruso chief financial officer vice president finance february caruso principal financial officer kapusta controller chief accounting officer february kapusta principal accounting officer beckerle director february beckerle coleman director february coleman davis director february davis davis director february davis signature title date lindquist director february lindquist mcclellan director february mcclellan mulcahy director february mulcahy perez director february perez prince director february prince washington director february washington williams director february williams exhibit index reg exhibit table description item exhibit restate certificate incorporation effective february file document bylaw company amend effective january incorporate reference exhibit registrant form current report file january request security exchange commission registrant furnish copy instrument define right holder longterm debt registrant longterm incentive plan incorporate reference exhibit registrant registration statement file commission file form restrict share nonemployee directors longterm incentive plan incorporate reference exhibit registrant form current report file august form stock option certificate restrict share unit certificate performance share unit certificate longterm incentive plan incorporate reference exhibit registrant form current report file january longterm incentive plan incorporate reference appendix registrant proxy statement file commission march form stock option certificate restrict share unit certificate performance share unit certificate longterm incentive plan incorporate reference exhibit registrant form quarterly report file executive incentive plan amend incorporate reference exhibit registrant annual report year end december domestic deferred compensation certificate extra compensation plan incorporate reference exhibit registrant annual report year end december amendment certificate extra compensation plan effective january incorporate reference exhibit registrant annual report year end december certificate longterm performance plan incorporate reference exhibit registrant form quarterly report quarter end september amend restate deferred fee plan director incorporate reference exhibit registrant annual report year end january executive income deferral plan amend restate incorporated reference exhibit registrant form quarterly report quarter end september excess saving plan incorporate reference exhibit registrant annual report year end december amendments johnson johnson excess saving plan effective january incorporate reference exhibit registrant annual report year end december excess benefit plan supplemental retirement plan incorporate reference exhibit registrant annual report year end january amendment excess benefit plan johnson johnson affiliate company effective january incorporate reference exhibit registrant annual report year end december amendment excess benefit plan johnson johnson affiliate company effective january incorporate reference exhibit registrant annual report year end december executive life plan agreement incorporate reference exhibit registrant form annual report year end january executive life plan agreement closure letter incorporate reference exhibit registrant form quarterly report quarter end march johnson johnson retirement savings plan johnson johnson savings plan union represent employees johnson johnson saving plan incorporate reference exhibit registrant form file commission employment agreement paulus stoffels incorporate reference exhibit registrant form quarterly report quarter end september reg exhibit table description item exhibit summary employment arrangement sandra peterson incorporate reference exhibit registrant annual report year end december severance pay plan johnson johnson affiliate company amend restate october incorporate reference exhibit registrant form quarterly report quarter end september amendment severance pay plan johnson johnson affiliate company amend restate effective october incorporate reference exhibit registrant form quarterly report quarter end june second amendment severance pay plan johnson johnson affiliate company amend restate effective october file document statement computation ratio earning fix charge file document subsidiary file document consent independent register public accounting firm file document certification chief executive officer pursuant section sarbanesoxley act file document certification chief financial officer pursuant section sarbanesoxley act file document certification chief executive officer pursuant section sarbanesoxley act furnish document certification chief financial officer pursuant section sarbanesoxley act furnish document cautionary statement pursuant private security litigation reform act safe harbor forwardlooke statement file document xbrl extensible business report language follow material report fiscal year end january format extensive business report language xbrl consolidate balance sheet consolidated statement earning iii consolidated statement comprehensive income consolidate statement equity consolidate statement cash flow note consolidated financial statement management contract compensatory plan copy exhibit list provide charge shareholder submit write request specify desire exhibit secretary principal executive office company exhibit restate certificate incorporation johnson johnson pursuant section new jersey business corporation act johnson johnson restates integrate certificate incorporation heretofore amend restate read follow corporation johnson johnson second address corporation register office johnson johnson plaza new brunswick new jersey corporation register agent address johnson johnson purpose corporation organize engage activity purpose corporation organize new jersey business corporation act fourth aggregate number share class stock corporation authority issue billion twentytwo million divide million share prefer stock par value billion million share common stock par value dollar share class stock corporation issue time time manner lawful consideration time time fix board director case share prefer stock board director shall discretion determine portion consideration receive share allocate capital surplus designation preference vote right restriction limitation prefer stock common stock corporation shall follow preferred stock prefer stock issue time time board director amount prefer stock series hereinafter set forth provide share prefer stock time outstanding creation series designation right preference limitation description term thereof number share shall subject term article fourth set forth amendment certificate incorporation corporation board director expressly authorize accordance law state new jerseyin particular limit general power provide right preference priorities inconsistent corporation certificate incorporation permit fix law state new jersey effect time creation series board director corporation expressly authorize create provide issuance series prefer stock entitle holder thereof cumulative noncumulative partially cumulative dividend entitle holder thereof receive dividend payable parity preference dividend payable class series capital stock corporation entitle holder thereof preferential right liquidation distribution asset corporation convertible option holder corporation share class class capital stock corporation series class class redeemable option corporation cash bond property price price period period condition board director shall provide include provision creation sink fund redemption thereof lack voting right limit voting right enjoy special multiple voting right board director change designation right preference limitation description term number share series share theretofore issue common stock share corporation capital stock outstanding time restate certificate incorporation shall effective shall designate common stock corporation holder common stock corporation shall entitle vote share common stock matter submit holder common stock corporation general holder stock corporation class authorize shall right holder right board director discretion determine purchase subscribe acquire share stock corporation class authorize partpaid receipt allotmentcertificate respect share security convertible exchangeable share warrant instrument evidence right option subscribe purchase acquire share share receipt certificate security warrant instrument unissue issue acquire corporation subject forego provision article fourth board director shall power discretion declare pay dividend share stock corporation class asset corporation lawfully available payment dividend certificate incorporation contrary notwithstanding holder share stock corporation class shall right dividend thereon dividend shall declare board director aforesaid board director shall power provide issuance subsidiary company capital stock bond obligation convertible option holder subsidiary company andor corporation share class class series class class capital stock corporation right option acquire share term fix board director term subsidiary company shall mean corporation corporation hold directly indirectly majority outstanding voting stock fifth number director constitute board director corporation current time restatement certificate incorporation address director johnson johnson plaza new brunswick new jersey name follow alex gorsky mary beckerle mary sue coleman scott davis ian davis susan lindquist mark mcclellan anne mulcahy william perez charles prince eugene washington ronald awilliams directorship fill reason increase number director fill election majority director office sixth board director shall power alter amend repeal bylaw corporation subject reserve power shareholder alter repeal bylaw boardseventh propose amendment certificate incorporation corporation shall adopt receive affirmative vote majority vote cast holder share entitle vote thereon addition class series share entitle vote thereon class affirmative vote majority vote cast class vote eighth extent law state new jersey exist date hereof amend permit limitation elimination liability director officer director officer corporation shall personally liable corporation shareholder damage breach duty owe corporation shareholder amendment repeal article adoption provision restate certificate incorporation inconsistent article shall apply effect liability allege liability director officer corporation respect act omission director officer occur prior amendment repeal adoption ninth board director corporation shall consist eighteen member actual number determine board director time time director corporation remove vote shareholder cause witness whereof johnson johnson cause restate certificate incorporation duly execute day february johnson johnson bys alex gorsky alex gorsky presidentexhibit second amendment severance pay plan johnson johnson affiliate company amend restate effective october pursuant action pension benefit committee johnson johnson meeting hold september severance pay plan johnson johnson affiliate company plan amend follow effective respect individual give notice termination september article biii amend read follow eligible employee eligible benefit provide article employment terminate result follow event refusal position johnson johnson company sole discretion pension benefit committee comparable mean new position result reduction eligible employee base pay salary minimis reduction pay grade eligible employee current position primary work location mile radius eligible employee current primary work location acceptance employment johnson johnson company nov lisa blair davis date lisa blair davis member pension benefits committee johnson johnson exhibit johnson johnson subsidiaries statement computation ratio earning fix charge dollar million december december december january january determination earning earning provision taxis income fix charge capitalize interest total earning define fix charge estimate interest portion rent expense interest expense capitalization interest total fix charge ratio earning fix charge ratio earning fix charge compute divide sum earning provision taxis income fix charge fix charge fix charge represent interest expense interest capitalize amortization debt discount appropriate interest factor operating leasesexhibit subsidiary johnson johnson new jersey corporation international subsidiary show january certain subsidiary international subsidiary name significant aggregate johnson johnson subsidiary entity jurisdiction subsidiary organization subsidiaries acclarent inc delaware advanced sterilization product services inc new jersey alios biopharma inc delaware alza corporation delaware alza land management inc delaware animas corporation delaware aragon pharmaceuticals inc delaware biosense webster inc california calibra medical inc delaware cna development llc delaware codman shurtleff inc new jersey coherex medical inc delaware cordis financing corporation delaware cordis llc delaware depuy mitek llc massachusetts depuy orthopaedics inc indiana depuy products inc indiana depuy spine llc ohio depuy synthes products inc delaware depuy synthes sales inc massachusetts depuy synthes inc delaware diabetes diagnostics inc delaware ethicon endosurgery inc ohio ethicon endosurgery llc delaware ethicon llc delaware ethicon llc texas ethicon inc new jersey heartport inc delaware holdings nevada inc nevada janssen biotech inc pennsylvania janssen global services llc new jersey janssen oncology inc delaware janssen ortho llc delaware janssen pharmaceuticals inc pennsylvania janssen product new jersey janssen research development llc new jerseyjanssen scientific affairs llc new jersey janssen supply group llc pennsylvania janssencilag manufacturing llc delaware jjhc llc delaware jnj international investment llc delaware johnson johnson middle east inc new jersey johnson johnson consumer inc new jersey johnson johnson finance corporation new jersey johnson johnson health care systems inc new jersey johnson johnson innovation jjdc inc new jersey johnson johnson international new jersey johnson johnson japan inc new jerseyjurisdiction subsidiary organization johnson johnson services inc new jersey johnson johnson urban renewal associates new jersey johnson johnson vision care inc florida jom pharmaceutical services inc delaware lifescan inc california mcneil consumer pharmaceutical new jersey mcneil healthcare llc delaware mcneil mmp llc new jersey mcneil nutritionals llc delaware mentor texas delaware mentor worldwide llc delaware micrus endovascular llc delaware middlesex assurance company limited vermont noramco inc georgia novira therapeutics inc delaware omrix biopharmaceutical inc delaware ortho biologics llc delaware patriot pharmaceuticals llc pennsylvania rutan realty llc new jersey scios llc delaware sterilmed inc minnesota synthes usa products llc delaware synthes usa llc delaware synthes inc delaware anspach effort llc florida international subsidiary apsis france apsis germany gmbh germany beijing dabao cosmetics ltd china berna rhein netherlands biosense webster israel ltd israel cilag advanced technologies gmbh switzerland cilag switzerland cilag gmbh international switzerland cilag holding switzerland cilag holding finance unlimited company ireland cilag pharmaceuticals gmbh switzerland cilag products gmbh switzerland cordis mexico mexico cordis europa netherlands corimmun gmbh germanycovagen switzerland crucell holland netherlands crucell netherlands depuy ireland ireland depuy france france depuy international limited united kingdom depuy synthes apollo limited irelandjurisdiction subsidiary organization depuy synthe eos limited ireland depuy synthes gorgan limited ireland depuy synthes jason limited ireland depuy synthes leto sarl luxembourg ees mexico ethicon france ethicon ireland ireland ethicon holdings ireland ethicon women health urology sarl switzerland ethnor farmaceutica venezuela fms future medical system switzerland gme healthcare bvba belgium general services cvba belgium janssen alzheimer immunotherapy hold limited ireland janssen biologics ireland ireland janssen biologics netherlands janssen cilag farmaceutica argentina janssen mexico mexico janssen inc canada janssen infectious diseasesdiagnostic bvba belgium janssen irish finance company ireland janssen korea ltd korea republic janssen pharmaceutica belgium janssen pharmaceutical ireland janssen pharmaceutical holdings ireland janssen pharmaceutical international holdings ireland janssen pharmaceutical japan janssen pharmaceutical sciences unlimited company ireland janssen ireland ireland janssen sciences ireland ireland janssen vaccine corp korea republic janssen vaccines switzerland janssencilag france janssencilag sweden janssencilag switzerland janssencilag norway janssencilag denmark janssencilag netherlands janssencilag farmaceutica ltda brazil janssencilag farmaceutica lda portugal janssencilag gmbh germanyjanssencilag kft hungary janssencilag limited thailand janssencilag limited united kingdom janssencilag belgium janssencilag finland janssencilag pharma gmbh austria janssencilag pharmaceutical saci greecejurisdiction subsidiary organization janssencilag pty ltd australia janssencilag colombia janssencilag spa italy janssencilag venezuela janssencilag spain janssencilag mexico health care ltd israel jjc acquisition company netherlands johnson johnson china investment ltd china johnson johnson china ltd china johnson johnson hong kong limited hong kong johnson johnson ireland limited ireland johnson johnson new zealand limited new zealand johnson johnson philippines inc philippines johnson johnson proprietary limited south africa johnson johnson thailand ltd thailand johnson johnson sweden johnson johnson switzerland johnson johnson belgium finance company belgium johnson johnson consumer thailand limited thailand johnson johnson consumer netherlands johnson johnson consumer holding france france johnson johnson consumer services eame ltd united kingdom johnson johnson argentina sac argentina johnson johnson chile chile johnson johnson colombia colombia johnson johnson mexico mexico johnson johnson venezuela venezuela johnson johnson del ecuador ecuador johnson johnson del peru peru johnson johnson brasil industria comercio produtos para saude ltda brazil johnson johnson european treasury company ireland johnson johnson finance limited united kingdom johnson johnson financial services gmbh germany johnson johnson gesellschaft mbh austria johnson johnson gmbh germany johnson johnson group holdings gmbh germany johnson johnson hellas commercial industrial greece johnson johnson holding gmbh germany johnson johnson holdings japan johnson johnson inc canadajohnson johnson industrial ltda brazil johnson johnson innovation limited united kingdom johnson johnson international financial services company ireland johnson johnson japan johnson johnson kft hungary johnson johnson korea sell distribution limited liability company korea republic johnson johnson korea ltd korea republic ofjurisdiction subsidiary organization johnson johnson limitada portugal johnson johnson limited united kingdom johnson johnson llc russian federation johnson johnson luxembourg finance company sarl luxembourg johnson johnson management limited united kingdom johnson johnson medical china ltd china johnson johnson medical shanghai ltd china johnson johnson medical suzhou ltd china johnson johnson medical netherlands johnson johnson medical gmbh germany johnson johnson medical korea limited korea republic johnson johnson medical limited united kingdom johnson johnson medical mexico mexico johnson johnson medical belgium johnson johnson medical products gmbh austria johnson johnson medical pty ltd australia johnson johnson medical argentina johnson johnson medical spa italy johnson johnson medical scs venezuela johnson johnson medikal sanayi ticaret limited sirketi turkey johnson johnson middle east fzllc united arab emirates johnson johnson nordic sweden johnson johnson pacific pty limited australia johnson johnson poland poland johnson johnson private limited india johnson johnson pte ltd singapore johnson johnson pty limited australia johnson johnson sante beaute france france johnson johnson spa italy johnson johnson sdn bhd malaysia johnson johnson sihhi malzeme sanayi ticaret limited sirketi turkey johnson johnson swiss finance company limited united kingdom johnson johnson taiwan ltd taiwan johnson johnson treasury company limited united kingdom johnson johnson vision care ireland ireland johnson johnson prodaja medicinskih farmacevtskih izdelkov doo slovenia johnson johnson spain johnson johnson mexico johnson johnson sro czech republic johnson johnson sro slovakiajohnson johnson medical pty limited south africa latam international investment company ireland latam property holdings ireland lifescan france lifescan scotland limited united kingdom mcneil sweden mcneil healthcare limited united kingdom mcneil products limit united kingdomjurisdiction subsidiary organization mcneil sweden sweden medos international sarl switzerland medos sarl switzerland mentor netherlands mentor medical system netherlands mentor medical system netherlands obtech medical sarl switzerland omj ireland ireland omj holdings ireland omrix biopharmaceutical ltd israel johnson johnson indonesia indonesia shanghai elsker mother baby ltd china shanghai johnson johnson pharmaceuticals ltd china spectrum vision limit liability company russian federation synthe suzhou medical ltd china synthes australia pty ltd australia synthes colombia sas colombia synthe gmbh germany synthe gmbh switzerland synthes holding switzerland synthes limited united kingdom synthe lux finance srl luxembourg synthes luxembourg srl luxembourg synthes medical immobilien gmbh germany synthes produktions gmbh switzerland synthes tuttlingen gmbh germany tasmanian alkaloid pty ltd australia turnbuckle investment company ireland vania expansion france xianjanssen pharmaceutical ltd china limited united kingdomexhibit consent independent register public accounting firm consent incorporation reference registration statement form nos form nos johnson johnson report date february relate financial statement effectiveness internal control financial reporting appear pricewaterhousecooper llp pricewaterhousecooper llp florham park new jersey february exhibit certification chief executive officer pursuant section sarbanesoxley act alex gorsky certify review annual report fiscal year end january report johnson johnson company base knowledge report contain untrue statement material fact omit state material fact necessary statement light circumstance statement misleading respect period cover report base knowledge financial statement financial information include report fairly present material respect financial condition result operation cash flow company period present report company certify officer responsible establish maintain disclosure control procedure define exchange act rule internal control financial reporting define exchange act rules company design disclosure control procedure cause disclosure control procedure design supervision ensure material information relate company include consolidated subsidiary known entity particularly period report prepare design internal control financial reporting cause internal control financial reporting design supervision provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle evaluated effectiveness company disclosure control procedure present report conclusion effectiveness disclosure control procedure end period cover report base evaluation disclose report change company internal control financial reporting occur company recent fiscal quarter company fourth fiscal quarter case annual report materially affect reasonably likely materially affect company internal control financial reporting company certify officer disclose base recent evaluation internal control financial reporting company auditor audit committee company board director person perform equivalent function significant deficiency material weakness design operation internal control financial reporting reasonably likely adversely affect company ability record process summarize report financial information fraud material involve management employee significant role company internal control financial reporting alex gorsky alex gorsky chief executive officer date february exhibit certification chief financial officer pursuant section sarbanesoxley act dominic caruso certify review annual report fiscal year end january report johnson johnson company base knowledge report contain untrue statement material fact omit state material fact necessary statement light circumstance statement misleading respect period cover report base knowledge financial statement financial information include report fairly present material respect financial condition result operation cash flow company period present report company certify officer responsible establish maintain disclosure control procedure define exchange act rule internal control financial reporting define exchange act rules company design disclosure control procedure cause disclosure control procedure design supervision ensure material information relate company include consolidated subsidiary known entity particularly period report prepare design internal control financial reporting cause internal control financial reporting design supervision provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle evaluated effectiveness company disclosure control procedure present report conclusion effectiveness disclosure control procedure end period cover report base evaluation disclose report change company internal control financial reporting occur company recent fiscal quarter company fourth fiscal quarter case annual report materially affect reasonably likely materially affect company internal control financial reporting company certify officer disclose base recent evaluation internal control financial reporting company auditor audit committee company board director person perform equivalent function significant deficiency material weakness design operation internal control financial reporting reasonably likely adversely affect company ability record process summarize report financial information fraud material involve management employee significant role company internal control financial reporting dominic caruso dominic caruso chief financial officer date february exhibit certification chief executive officer pursuant section sarbanesoxley act undersign alex gorsky chief executive officer johnson johnson new jersey corporation company pursuant usc adopt pursuant section sarbanesoxley act certifie good knowledge company annual report fiscal year end january report fully complie requirement section securities exchange act information contain report fairly present material respect financial condition result operation company alex gorsky alex gorsky chief executive officer date february certification furnish sec report pursuant section sarbanesoxley act shall extent require act deem file company purpose section securities exchange act amend subject liability sectionexhibit certification chief financial officer pursuant section sarbanesoxley act undersign dominic caruso chief financial officer johnson johnson new jersey corporation company pursuant usc adopt pursuant section sarbanesoxley act certifie good knowledge company annual report fiscal year end january report fully complie requirement section securities exchange act information contain report fairly present material respect financial condition result operation company dominic caruso dominic caruso chief financial officer date february certification furnish sec report pursuant section sarbanesoxley act shall extent require act deem file company purpose section securities exchange act amend subject liability sectionexhibit cautionary statement pursuant private security litigation reform act safe harbor forwardlooke statement company time time certain forwardlooking statement publiclyrelease material write oral forwardlooking statement relate strictly historical current fact reflect management assumption view plan objective projection future forwardlooke statement identify use word plan expect anticipate estimate word similar meaning conjunction thing discussion future operation financial performance company strategy growth product development regulatory approval market position expenditure forwardlooke statement base current belief expectation assumption future event statement subject uncertainty risk change difficult predict outside company control investor realize underlying assumption prove inaccurate know unknown risk uncertainty materialize actual result vary materially company expectation projection investor caution place undue reliance forwardlooke statement furthermore company undertake update forwardlooke statement result new information future event development important factor cause company actual result differ materially express imply company forwardlooke statement follow economic factor include inflation fluctuation interest rate currency exchange rate potential effect fluctuation revenue expense result margin competitive factor include technological advance achieve patent attain competitor new product introduce competitor market share gain competitor brand product biosimilar generic productsstore brand challenge company patent competitor allegation company product infringe patent party adversely affect company ability sell product question result loss sale loss market exclusivity require payment past damage future royalty particular firm file abbreviate new drug application biosimilar biological product application fda challenge coverage andor validity company patent seek market generic biosimilar form company key pharmaceutical product prior expiration applicable patent cover product event company successful defending result lawsuit generic biosimilar version product issue introduce market result potential substantial market share revenue loss impact patent expiration company business operating result patent expire competitor able legally produce market similar product technology include biosimilar generic material adverse effect company sale result operation significant change customer relationship change behavior spend pattern purchaser health care product service include delay medical procedure ration prescription medication reduce frequency physician visit forego health care insurance coverage impact international operation financial instability international economy sovereign risk possible imposition governmental control restrictive economic policy unstable international government legal system health care change country result pricing pressure include continued consolidation health care provider trend manage care health care cost containment shift government primary payer health care expense law regulation relate sale promotion reimbursement access pricing generally potential expect benefit opportunity relate planned restructure action medical device segment realize long realize expect include require consultation procedure relate restructure workforce uncertainty commercial success new exist product ability company successfully execute strategic plan include restructuring plan government law regulation affect international operation include relate taxis price reimbursement regulatory approval new product license patent right environmental protection conflictmineral possible drug reimportation legislation trade monetary fiscal policy security law compliance competition research internally externally source involve development improvement new exist product process particularly significant result time time product process obsolescence development new improved product important company success area business investment development commercialization collaboration externally source innovation inherently risky guarantee success challenge difficulty inherent product development include potential inability successfully continue technological innovation complete clinical trial obtain regulatory approval internationally gain maintain market approval product possibility encounter infringement claim competitor respect patent intellectual property right preclude delay commercialization product challenge involve postmarket surveillance activity study datum collection analysis real world context product efficacy safety concern base scientific evidence result product withdrawal recall regulatory action fda international counterpart decline sale significant litigation government action adverse company include product liability claim patent infringement claim antitrust claim uncertain nature litigation government action outcome matter result charge excess establish accrual product liability insurance product limit cost prohibitive unavailable increase scrutiny health care industry government agency state attorney general result investigation prosecution carry risk significant civil criminal penalty include limited debarment government business failure meet compliance obligation mcneilppc inc consent decree corporate integrity agreement johnson johnson pharmaceutical affiliates depuy synthe company compliance agreement government government agency result significant sanction difficulty delay manufacture internally supply chain cause voluntary involuntary business interruption shutdown product shortage substantial modification business practice operation withdrawal suspension current product market possible civil penalty criminal prosecution interruption breach company computer communication system company vendor include computer virus hack cyberattack impair company ability conduct business communicate internally customer result theft trade secret misappropriation asset compromise privacy sensitive information belong company customer business partner impact business combination include acquisition divestiture company externally pharmaceutical medical device consumer industry potential expect strategic benefit opportunity acquisition divestiture company realize long realize expect market condition possibility ongoing share repurchase program suspend discontinue reliance global supply chain production distribution process complex subject increase regulatory requirement adversely affect source supply pricing material product involve multiple party require significant capital expenditure subject lengthy regulatory approval financial distress bankruptcy experience significant customer supplier impair ability case purchase company product pay product previously purchase meet obligation company supply arrangement possibility internal revenue service assert contrary position challenge transaction consummate connection acquisition synthes inc tax perspective challenge total purchase price synthe share treat subject applicable tax approximately statutory rate company plus interest change global climate extreme weather natural disaster affect demand company product service cause disruption manufacture distribution network alter availability good service supply chain affect overall design integrity company product operation impact political economic condition terrorist attack part world military action overseas instability financial market result terrorism military action issuance new revise accounting standard financial accounting standard board securities exchange commission foregoing list set forth factor impact company ability achieve result describe forwardlooke statement investor understand possible predict identify factor consider list complete statement potential risk uncertainty company identify factor list permit private security litigation reform act